{"id": "AIMed.d11.s88_AIMed.d11.s88.p0", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ([E1]ErbB-1[/E1], neu/[E2]ErbB-2[/E2], ErbB-3, and ErbB-4) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-1", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-2", "entity_2_idx": [[129, 135]], "entity_2_idx_in_text_with_entity_marker": [142, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p1", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ([E1]ErbB-1[/E1], neu/ErbB-2, [E2]ErbB-3[/E2], and ErbB-4) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-1", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-3", "entity_2_idx": [[137, 143]], "entity_2_idx_in_text_with_entity_marker": [150, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p2", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ([E1]ErbB-1[/E1], neu/ErbB-2, ErbB-3, and [E2]ErbB-4[/E2]) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-1", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-4", "entity_2_idx": [[149, 155]], "entity_2_idx_in_text_with_entity_marker": [162, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p3", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/[E1]ErbB-2[/E1], [E2]ErbB-3[/E2], and ErbB-4) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-2", "entity_1_idx": [[129, 135]], "entity_1_idx_in_text_with_entity_marker": [133, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-3", "entity_2_idx": [[137, 143]], "entity_2_idx_in_text_with_entity_marker": [150, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p4", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/[E1]ErbB-2[/E1], ErbB-3, and [E2]ErbB-4[/E2]) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-2", "entity_1_idx": [[129, 135]], "entity_1_idx_in_text_with_entity_marker": [133, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-4", "entity_2_idx": [[149, 155]], "entity_2_idx_in_text_with_entity_marker": [162, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p5", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, [E1]ErbB-3[/E1], and [E2]ErbB-4[/E2]) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-3", "entity_1_idx": [[137, 143]], "entity_1_idx_in_text_with_entity_marker": [141, 147], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-4", "entity_2_idx": [[149, 155]], "entity_2_idx_in_text_with_entity_marker": [162, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s90_AIMed.d11.s90.p0", "text": "RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that ErbB-1 and ErbB-3 were also significant predictors.", "text_with_entity_marker": "RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that [E1]ErbB-1[/E1] and [E2]ErbB-3[/E2] were also significant predictors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB-1", "entity_1_idx": [[213, 219]], "entity_1_idx_in_text_with_entity_marker": [217, 223], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-3", "entity_2_idx": [[224, 230]], "entity_2_idx_in_text_with_entity_marker": [237, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1119_AIMed.d131.s1119.p0", "text": "Expression cloning and characterization of a human IL-10 receptor.", "text_with_entity_marker": "Expression cloning and characterization of a human [E1-E2]IL-10[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10[/E1] receptor", "entity_2_idx": [[51, 65]], "entity_2_idx_in_text_with_entity_marker": [58, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1120_AIMed.d131.s1120.p0", "text": "cDNA clones encoding a human IL-10R (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.", "text_with_entity_marker": "cDNA clones encoding a human [E1]IL-10R[/E1] ([E2]hIL-10R[/E2]) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10R", "entity_2_idx": [[37, 44]], "entity_2_idx_in_text_with_entity_marker": [50, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1120_AIMed.d131.s1120.p1", "text": "cDNA clones encoding a human IL-10R (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.", "text_with_entity_marker": "cDNA clones encoding a human [E1]IL-10R[/E1] (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds [E2]hIL-10[/E2] specifically.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-10R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1120_AIMed.d131.s1120.p2", "text": "cDNA clones encoding a human IL-10R (hIL-10R) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL-10 specifically.", "text_with_entity_marker": "cDNA clones encoding a human IL-10R ([E1]hIL-10R[/E1]) from a Burkitt lymphoma cell line, BJAB, express a 90 to 110 kDa polypeptide in COS7 cells that binds [E2]hIL-10[/E2] specifically.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p0", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of [E1]hIL-10R[/E1] is 60% identical and 73% similar to mouse [E2]IL-10R[/E2] (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10R", "entity_2_idx": [[87, 93]], "entity_2_idx_in_text_with_entity_marker": [100, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p1", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of [E1]hIL-10R[/E1] is 60% identical and 73% similar to mouse IL-10R ([E2]mIL-10R[/E2]). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mIL-10R", "entity_2_idx": [[95, 102]], "entity_2_idx_in_text_with_entity_marker": [108, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p2", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of [E1]hIL-10R[/E1] is 60% identical and 73% similar to mouse IL-10R (mIL-10R). [E2]rIL-10R[/E2] expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "rIL-10R", "entity_2_idx": [[105, 112]], "entity_2_idx_in_text_with_entity_marker": [118, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p3", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of [E1]hIL-10R[/E1] is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an [E2]IL-3[/E2]-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-3", "entity_2_idx": [[129, 133]], "entity_2_idx_in_text_with_entity_marker": [142, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p4", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of [E1]hIL-10R[/E1] is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds [E2]hIL-10[/E2] with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p5", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of [E1]hIL-10R[/E1] is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to [E2]hIL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[285, 291]], "entity_2_idx_in_text_with_entity_marker": [298, 304], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p6", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse [E1]IL-10R[/E1] ([E2]mIL-10R[/E2]). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10R", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mIL-10R", "entity_2_idx": [[95, 102]], "entity_2_idx_in_text_with_entity_marker": [108, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p7", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse [E1]IL-10R[/E1] (mIL-10R). [E2]rIL-10R[/E2] expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10R", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "rIL-10R", "entity_2_idx": [[105, 112]], "entity_2_idx_in_text_with_entity_marker": [118, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p8", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse [E1]IL-10R[/E1] (mIL-10R). rIL-10R expressed in an [E2]IL-3[/E2]-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10R", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-3", "entity_2_idx": [[129, 133]], "entity_2_idx_in_text_with_entity_marker": [142, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p9", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse [E1]IL-10R[/E1] (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds [E2]hIL-10[/E2] with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10R", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p10", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse [E1]IL-10R[/E1] (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to [E2]hIL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10R", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[285, 291]], "entity_2_idx_in_text_with_entity_marker": [298, 304], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p11", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R ([E1]mIL-10R[/E1]). [E2]rIL-10R[/E2] expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mIL-10R", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "rIL-10R", "entity_2_idx": [[105, 112]], "entity_2_idx_in_text_with_entity_marker": [118, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p12", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R ([E1]mIL-10R[/E1]). rIL-10R expressed in an [E2]IL-3[/E2]-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mIL-10R", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-3", "entity_2_idx": [[129, 133]], "entity_2_idx_in_text_with_entity_marker": [142, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p13", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R ([E1]mIL-10R[/E1]). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds [E2]hIL-10[/E2] with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mIL-10R", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p14", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R ([E1]mIL-10R[/E1]). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to [E2]hIL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mIL-10R", "entity_1_idx": [[95, 102]], "entity_1_idx_in_text_with_entity_marker": [99, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[285, 291]], "entity_2_idx_in_text_with_entity_marker": [298, 304], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p15", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). [E1]rIL-10R[/E1] expressed in an [E2]IL-3[/E2]-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rIL-10R", "entity_1_idx": [[105, 112]], "entity_1_idx_in_text_with_entity_marker": [109, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-3", "entity_2_idx": [[129, 133]], "entity_2_idx_in_text_with_entity_marker": [142, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p16", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). [E1]rIL-10R[/E1] expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds [E2]hIL-10[/E2] with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "rIL-10R", "entity_1_idx": [[105, 112]], "entity_1_idx_in_text_with_entity_marker": [109, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p17", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). [E1]rIL-10R[/E1] expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to [E2]hIL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rIL-10R", "entity_1_idx": [[105, 112]], "entity_1_idx_in_text_with_entity_marker": [109, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[285, 291]], "entity_2_idx_in_text_with_entity_marker": [298, 304], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p18", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an [E1]IL-3[/E1]-dependent mouse pro-B cell line (Ba/F3) binds [E2]hIL-10[/E2] with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-3", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p19", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an [E1]IL-3[/E1]-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to [E2]hIL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-3", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[285, 291]], "entity_2_idx_in_text_with_entity_marker": [298, 304], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1121_AIMed.d131.s1121.p20", "text": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds hIL-10 with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to hIL-10.", "text_with_entity_marker": "The predicted amino acid sequence of hIL-10R is 60% identical and 73% similar to mouse IL-10R (mIL-10R). rIL-10R expressed in an IL-3-dependent mouse pro-B cell line (Ba/F3) binds [E1]hIL-10[/E1] with high affinity (200 to 250 pM), and the transfected cells exhibit a proliferative response to [E2]hIL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10", "entity_2_idx": [[285, 291]], "entity_2_idx_in_text_with_entity_marker": [298, 304], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1122_AIMed.d131.s1122.p0", "text": "Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "text_with_entity_marker": "Mouse [E1]IL-10[/E1] does not bind to [E2]hIL-10R[/E2], and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10R", "entity_2_idx": [[29, 36]], "entity_2_idx_in_text_with_entity_marker": [42, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1122_AIMed.d131.s1122.p1", "text": "Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "text_with_entity_marker": "Mouse [E1]IL-10[/E1] does not bind to hIL-10R, and [E2]hIL-10R[/E2]-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10R", "entity_2_idx": [[42, 49]], "entity_2_idx_in_text_with_entity_marker": [55, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1122_AIMed.d131.s1122.p2", "text": "Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "text_with_entity_marker": "Mouse [E1]IL-10[/E1] does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of [E2]IL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1122_AIMed.d131.s1122.p3", "text": "Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "text_with_entity_marker": "Mouse IL-10 does not bind to [E1]hIL-10R[/E1], and [E2]hIL-10R[/E2]-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[29, 36]], "entity_1_idx_in_text_with_entity_marker": [33, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10R", "entity_2_idx": [[42, 49]], "entity_2_idx_in_text_with_entity_marker": [55, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1122_AIMed.d131.s1122.p4", "text": "Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "text_with_entity_marker": "Mouse IL-10 does not bind to [E1]hIL-10R[/E1], and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of [E2]IL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[29, 36]], "entity_1_idx_in_text_with_entity_marker": [33, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1122_AIMed.d131.s1122.p5", "text": "Mouse IL-10 does not bind to hIL-10R, and hIL-10R-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of IL-10.", "text_with_entity_marker": "Mouse IL-10 does not bind to hIL-10R, and [E1]hIL-10R[/E1]-expressing Ba/F3 cells do not respond to the mouse cytokine, observations consistent with the known species specificity of [E2]IL-10[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[42, 49]], "entity_1_idx_in_text_with_entity_marker": [46, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1124_AIMed.d131.s1124.p0", "text": "In a number of human T cell clones, expression of hIL-10R mRNA is down-regulated after activation of the cells with anti-CD3 Ab and phorbol ester.", "text_with_entity_marker": "In a number of human T cell clones, expression of [E1]hIL-10R[/E1] mRNA is down-regulated after activation of the cells with anti-[E2]CD3[/E2] Ab and phorbol ester.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[50, 57]], "entity_1_idx_in_text_with_entity_marker": [54, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1126_AIMed.d131.s1126.p0", "text": "Like mIL-10R, hIL-10R is structurally related to IFNR.", "text_with_entity_marker": "Like [E1]mIL-10R[/E1], [E2]hIL-10R[/E2] is structurally related to IFNR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mIL-10R", "entity_1_idx": [[5, 12]], "entity_1_idx_in_text_with_entity_marker": [9, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-10R", "entity_2_idx": [[14, 21]], "entity_2_idx_in_text_with_entity_marker": [27, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1126_AIMed.d131.s1126.p1", "text": "Like mIL-10R, hIL-10R is structurally related to IFNR.", "text_with_entity_marker": "Like [E1]mIL-10R[/E1], hIL-10R is structurally related to [E2]IFNR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mIL-10R", "entity_1_idx": [[5, 12]], "entity_1_idx_in_text_with_entity_marker": [9, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNR", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1126_AIMed.d131.s1126.p2", "text": "Like mIL-10R, hIL-10R is structurally related to IFNR.", "text_with_entity_marker": "Like mIL-10R, [E1]hIL-10R[/E1] is structurally related to [E2]IFNR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hIL-10R", "entity_1_idx": [[14, 21]], "entity_1_idx_in_text_with_entity_marker": [18, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFNR", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d131.s1127_AIMed.d131.s1127.p0", "text": "Because IL-10 inhibits macrophage activation by IFN-gamma, this relationship suggests possible shared receptor or signal transduction pathway components.", "text_with_entity_marker": "Because [E1]IL-10[/E1] inhibits macrophage activation by [E2]IFN-gamma[/E2], this relationship suggests possible shared receptor or signal transduction pathway components.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-10", "entity_1_idx": [[8, 13]], "entity_1_idx_in_text_with_entity_marker": [12, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[48, 57]], "entity_2_idx_in_text_with_entity_marker": [61, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d73.s621_AIMed.d73.s621.p0", "text": "The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the B cell activation protein Bp50.", "text_with_entity_marker": "The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the [E1]B cell activation protein[/E1] [E2]Bp50[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B cell activation protein", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bp50", "entity_2_idx": [[136, 140]], "entity_2_idx_in_text_with_entity_marker": [149, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d73.s623_AIMed.d73.s623.p0", "text": "Unlabeled TNF-alpha and TNF-beta were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.", "text_with_entity_marker": "Unlabeled [E1]TNF-alpha[/E1] and [E2]TNF-beta[/E2] were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[24, 32]], "entity_2_idx_in_text_with_entity_marker": [37, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d73.s623_AIMed.d73.s623.p1", "text": "Unlabeled TNF-alpha and TNF-beta were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.", "text_with_entity_marker": "Unlabeled [E1]TNF-alpha[/E1] and TNF-beta were equally effective at displacing the binding of labeled [E2]TNF-alpha[/E2] to TNF-R expressing cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-alpha", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d73.s623_AIMed.d73.s623.p2", "text": "Unlabeled TNF-alpha and TNF-beta were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.", "text_with_entity_marker": "Unlabeled TNF-alpha and [E1]TNF-beta[/E1] were equally effective at displacing the binding of labeled [E2]TNF-alpha[/E2] to TNF-R expressing cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-beta", "entity_1_idx": [[24, 32]], "entity_1_idx_in_text_with_entity_marker": [28, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-alpha", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s549_AIMed.d64.s549.p0", "text": "We have isolated and characterized a cDNA clone, phFGFR, encoding a human fibroblast growth factor (FGF) receptor. phFGFR contains an open reading frame which encodes an 820 amino acid polypeptide with three immunoglobulin-like domains in the extracellular part and an intracellular split tyrosine kinase domain.", "text_with_entity_marker": "We have isolated and characterized a cDNA clone, [E1]phFGFR[/E1], encoding a human fibroblast growth factor (FGF) receptor. [E2]phFGFR[/E2] contains an open reading frame which encodes an 820 amino acid polypeptide with three immunoglobulin-like domains in the extracellular part and an intracellular split tyrosine kinase domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phFGFR", "entity_1_idx": [[49, 55]], "entity_1_idx_in_text_with_entity_marker": [53, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "phFGFR", "entity_2_idx": [[115, 121]], "entity_2_idx_in_text_with_entity_marker": [128, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s550_AIMed.d64.s550.p0", "text": "Transient expression in COS-1 cells and immunoprecipitation using an antiserum raised against a C-terminal peptide, gave rise to two components, representing mature (130 kDa) and precursor (115 kDa) forms of the phFGFR encoded polypeptide, which was denoted hFGFR-1.", "text_with_entity_marker": "Transient expression in COS-1 cells and immunoprecipitation using an antiserum raised against a C-terminal peptide, gave rise to two components, representing mature (130 kDa) and precursor (115 kDa) forms of the [E1]phFGFR[/E1] encoded polypeptide, which was denoted [E2]hFGFR-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phFGFR", "entity_1_idx": [[212, 218]], "entity_1_idx_in_text_with_entity_marker": [216, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hFGFR-1", "entity_2_idx": [[258, 265]], "entity_2_idx_in_text_with_entity_marker": [271, 278], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p0", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated [E1]acidic FGF[/E1] ([E2]aFGF[/E2]) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF", "entity_1_idx": [[26, 36]], "entity_1_idx_in_text_with_entity_marker": [30, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aFGF", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [51, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p1", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated [E1]acidic FGF[/E1] (aFGF) and [E2]basic FGF[/E2] (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF", "entity_1_idx": [[26, 36]], "entity_1_idx_in_text_with_entity_marker": [30, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "basic FGF", "entity_2_idx": [[48, 57]], "entity_2_idx_in_text_with_entity_marker": [61, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p2", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated [E1]acidic FGF[/E1] (aFGF) and basic FGF ([E2]bFGF[/E2]) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF", "entity_1_idx": [[26, 36]], "entity_1_idx_in_text_with_entity_marker": [30, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p3", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated [E1]acidic FGF[/E1] (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both [E2]aFGF[/E2] and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF", "entity_1_idx": [[26, 36]], "entity_1_idx_in_text_with_entity_marker": [30, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aFGF", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p4", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated [E1]acidic FGF[/E1] (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and [E2]bFGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF", "entity_1_idx": [[26, 36]], "entity_1_idx_in_text_with_entity_marker": [30, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p5", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF ([E1]aFGF[/E1]) and [E2]basic FGF[/E2] (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "basic FGF", "entity_2_idx": [[48, 57]], "entity_2_idx_in_text_with_entity_marker": [61, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p6", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF ([E1]aFGF[/E1]) and basic FGF ([E2]bFGF[/E2]) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p7", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF ([E1]aFGF[/E1]) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both [E2]aFGF[/E2] and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aFGF", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p8", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF ([E1]aFGF[/E1]) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and [E2]bFGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p9", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF (aFGF) and [E1]basic FGF[/E1] ([E2]bFGF[/E2]) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "basic FGF", "entity_1_idx": [[48, 57]], "entity_1_idx_in_text_with_entity_marker": [52, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p10", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF (aFGF) and [E1]basic FGF[/E1] (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both [E2]aFGF[/E2] and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "basic FGF", "entity_1_idx": [[48, 57]], "entity_1_idx_in_text_with_entity_marker": [52, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aFGF", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p11", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF (aFGF) and [E1]basic FGF[/E1] (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and [E2]bFGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "basic FGF", "entity_1_idx": [[48, 57]], "entity_1_idx_in_text_with_entity_marker": [52, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p12", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF ([E1]bFGF[/E1]) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both [E2]aFGF[/E2] and bFGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bFGF", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aFGF", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p13", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF ([E1]bFGF[/E1]) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and [E2]bFGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bFGF", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s551_AIMed.d64.s551.p14", "text": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both aFGF and bFGF.", "text_with_entity_marker": "Crosslinking of iodinated acidic FGF (aFGF) and basic FGF (bFGF) to transiently expressing COS-1 cells revealed a major band of 95 kDa, which was competed for by both [E1]aFGF[/E1] and [E2]bFGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[167, 171]], "entity_1_idx_in_text_with_entity_marker": [171, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s552_AIMed.d64.s552.p0", "text": "From Scatchard analyses, the Kd:s for binding of aFGF and bFGF to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.", "text_with_entity_marker": "From Scatchard analyses, the Kd:s for binding of [E1]aFGF[/E1] and [E2]bFGF[/E2] to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s552_AIMed.d64.s552.p1", "text": "From Scatchard analyses, the Kd:s for binding of aFGF and bFGF to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.", "text_with_entity_marker": "From Scatchard analyses, the Kd:s for binding of [E1]aFGF[/E1] and bFGF to [E2]hFGFR-1[/E2] were estimated to 25 pM and 41 pM, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "aFGF", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hFGFR-1", "entity_2_idx": [[66, 73]], "entity_2_idx_in_text_with_entity_marker": [79, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s552_AIMed.d64.s552.p2", "text": "From Scatchard analyses, the Kd:s for binding of aFGF and bFGF to hFGFR-1 were estimated to 25 pM and 41 pM, respectively.", "text_with_entity_marker": "From Scatchard analyses, the Kd:s for binding of aFGF and [E1]bFGF[/E1] to [E2]hFGFR-1[/E2] were estimated to 25 pM and 41 pM, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "bFGF", "entity_1_idx": [[58, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hFGFR-1", "entity_2_idx": [[66, 73]], "entity_2_idx_in_text_with_entity_marker": [79, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s553_AIMed.d64.s553.p0", "text": "Thus, phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF.", "text_with_entity_marker": "Thus, [E1]phFGFR[/E1] encodes a human FGF receptor with high affinity for both [E2]aFGF[/E2] and bFGF.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "phFGFR", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aFGF", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s553_AIMed.d64.s553.p1", "text": "Thus, phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF.", "text_with_entity_marker": "Thus, [E1]phFGFR[/E1] encodes a human FGF receptor with high affinity for both aFGF and [E2]bFGF[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "phFGFR", "entity_1_idx": [[6, 12]], "entity_1_idx_in_text_with_entity_marker": [10, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d64.s553_AIMed.d64.s553.p2", "text": "Thus, phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF.", "text_with_entity_marker": "Thus, phFGFR encodes a human FGF receptor with high affinity for both [E1]aFGF[/E1] and [E2]bFGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aFGF", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bFGF", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1766_AIMed.d205.s1766.p0", "text": "Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5.", "text_with_entity_marker": "Thymocyte activation induces the association of [E1]phosphatidylinositol 3-kinase[/E1] and [E2]pp120[/E2] with CD5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatidylinositol 3-kinase", "entity_1_idx": [[48, 77]], "entity_1_idx_in_text_with_entity_marker": [52, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp120", "entity_2_idx": [[82, 87]], "entity_2_idx_in_text_with_entity_marker": [95, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1766_AIMed.d205.s1766.p1", "text": "Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5.", "text_with_entity_marker": "Thymocyte activation induces the association of [E1]phosphatidylinositol 3-kinase[/E1] and pp120 with [E2]CD5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "phosphatidylinositol 3-kinase", "entity_1_idx": [[48, 77]], "entity_1_idx_in_text_with_entity_marker": [52, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[93, 96]], "entity_2_idx_in_text_with_entity_marker": [106, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1766_AIMed.d205.s1766.p2", "text": "Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5.", "text_with_entity_marker": "Thymocyte activation induces the association of phosphatidylinositol 3-kinase and [E1]pp120[/E1] with [E2]CD5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp120", "entity_1_idx": [[82, 87]], "entity_1_idx_in_text_with_entity_marker": [86, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[93, 96]], "entity_2_idx_in_text_with_entity_marker": [106, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1768_AIMed.d205.s1768.p0", "text": "Antibody-mediated cross-linking studies or studies on CD5 knockout mice implicate CD5 as a co-stimulatory or negative regulatory molecule.", "text_with_entity_marker": "Antibody-mediated cross-linking studies or studies on [E1]CD5[/E1] knockout mice implicate [E2]CD5[/E2] as a co-stimulatory or negative regulatory molecule.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD5", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1770_AIMed.d205.s1770.p0", "text": "Y429 and Y441 occur in an imperfect immunoreceptor tyrosine-based activation motif (ITAM)-like sequence.", "text_with_entity_marker": "Y429 and Y441 occur in an imperfect [E1]immunoreceptor tyrosine-based activation motif[/E1] ([E2]ITAM[/E2])-like sequence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "immunoreceptor tyrosine-based activation motif", "entity_1_idx": [[36, 82]], "entity_1_idx_in_text_with_entity_marker": [40, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITAM", "entity_2_idx": [[84, 88]], "entity_2_idx_in_text_with_entity_marker": [97, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1771_AIMed.d205.s1771.p0", "text": "We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated ITAM, interacts with CD5 following T cell activation.", "text_with_entity_marker": "We investigated whether [E1]phosphatidylinositol (PI) 3-kinase[/E1], which binds to tyrosine-phosphorylated [E2]ITAM[/E2], interacts with CD5 following T cell activation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "phosphatidylinositol (PI) 3-kinase", "entity_1_idx": [[24, 58]], "entity_1_idx_in_text_with_entity_marker": [28, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITAM", "entity_2_idx": [[99, 103]], "entity_2_idx_in_text_with_entity_marker": [112, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1771_AIMed.d205.s1771.p1", "text": "We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated ITAM, interacts with CD5 following T cell activation.", "text_with_entity_marker": "We investigated whether [E1]phosphatidylinositol (PI) 3-kinase[/E1], which binds to tyrosine-phosphorylated ITAM, interacts with [E2]CD5[/E2] following T cell activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatidylinositol (PI) 3-kinase", "entity_1_idx": [[24, 58]], "entity_1_idx_in_text_with_entity_marker": [28, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[120, 123]], "entity_2_idx_in_text_with_entity_marker": [133, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1771_AIMed.d205.s1771.p2", "text": "We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated ITAM, interacts with CD5 following T cell activation.", "text_with_entity_marker": "We investigated whether phosphatidylinositol (PI) 3-kinase, which binds to tyrosine-phosphorylated [E1]ITAM[/E1], interacts with [E2]CD5[/E2] following T cell activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ITAM", "entity_1_idx": [[99, 103]], "entity_1_idx_in_text_with_entity_marker": [103, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[120, 123]], "entity_2_idx_in_text_with_entity_marker": [133, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1772_AIMed.d205.s1772.p0", "text": "PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "text_with_entity_marker": "[E1]PI 3-kinase[/E1] activity and the regulatory [E2]p85[/E2] subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p85", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1772_AIMed.d205.s1772.p1", "text": "PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "text_with_entity_marker": "[E1]PI 3-kinase[/E1] activity and the regulatory p85 subunit of [E2]PI 3-kinase[/E2] associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI 3-kinase", "entity_2_idx": [[55, 66]], "entity_2_idx_in_text_with_entity_marker": [68, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1772_AIMed.d205.s1772.p2", "text": "PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "text_with_entity_marker": "[E1]PI 3-kinase[/E1] activity and the regulatory p85 subunit of PI 3-kinase associated with [E2]CD5[/E2] in pervanadate-stimulated, but not in unstimulated thymocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1772_AIMed.d205.s1772.p3", "text": "PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "text_with_entity_marker": "PI 3-kinase activity and the regulatory [E1]p85[/E1] subunit of [E2]PI 3-kinase[/E2] associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI 3-kinase", "entity_2_idx": [[55, 66]], "entity_2_idx_in_text_with_entity_marker": [68, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1772_AIMed.d205.s1772.p4", "text": "PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "text_with_entity_marker": "PI 3-kinase activity and the regulatory [E1]p85[/E1] subunit of PI 3-kinase associated with [E2]CD5[/E2] in pervanadate-stimulated, but not in unstimulated thymocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1772_AIMed.d205.s1772.p5", "text": "PI 3-kinase activity and the regulatory p85 subunit of PI 3-kinase associated with CD5 in pervanadate-stimulated, but not in unstimulated thymocytes.", "text_with_entity_marker": "PI 3-kinase activity and the regulatory p85 subunit of [E1]PI 3-kinase[/E1] associated with [E2]CD5[/E2] in pervanadate-stimulated, but not in unstimulated thymocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PI 3-kinase", "entity_1_idx": [[55, 66]], "entity_1_idx_in_text_with_entity_marker": [59, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1773_AIMed.d205.s1773.p0", "text": "Cellular p85 as well as the recombinant Src homology 2 (SH2) domains of p85 bound a tyrosine-phosphorylated peptide encompassing Y463 with approximately threefold greater affinity than a doubly tyrosine-phosphorylated Y429-Y441 peptide.", "text_with_entity_marker": "Cellular [E1]p85[/E1] as well as the recombinant Src homology 2 (SH2) domains of [E2]p85[/E2] bound a tyrosine-phosphorylated peptide encompassing Y463 with approximately threefold greater affinity than a doubly tyrosine-phosphorylated Y429-Y441 peptide.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p85", "entity_2_idx": [[72, 75]], "entity_2_idx_in_text_with_entity_marker": [85, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1775_AIMed.d205.s1775.p0", "text": "A 120-kDa phosphoprotein (pp120) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.", "text_with_entity_marker": "A [E1]120-kDa phosphoprotein[/E1] ([E2]pp120[/E2]) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "120-kDa phosphoprotein", "entity_1_idx": [[2, 24]], "entity_1_idx_in_text_with_entity_marker": [6, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp120", "entity_2_idx": [[26, 31]], "entity_2_idx_in_text_with_entity_marker": [39, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1775_AIMed.d205.s1775.p1", "text": "A 120-kDa phosphoprotein (pp120) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.", "text_with_entity_marker": "A [E1]120-kDa phosphoprotein[/E1] (pp120) associated with [E2]CD5[/E2] and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "120-kDa phosphoprotein", "entity_1_idx": [[2, 24]], "entity_1_idx_in_text_with_entity_marker": [6, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1775_AIMed.d205.s1775.p2", "text": "A 120-kDa phosphoprotein (pp120) associated with CD5 and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.", "text_with_entity_marker": "A 120-kDa phosphoprotein ([E1]pp120[/E1]) associated with [E2]CD5[/E2] and specifically with the Y429-Y441 phosphopeptide in stimulated thymocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp120", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1776_AIMed.d205.s1776.p0", "text": "We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and pp120 to CD5.", "text_with_entity_marker": "We conclude that stimulation of thymocytes with pervanadate induces the recruitment of [E1]PI 3-kinase[/E1] and [E2]pp120[/E2] to CD5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[87, 98]], "entity_1_idx_in_text_with_entity_marker": [91, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp120", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1776_AIMed.d205.s1776.p1", "text": "We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and pp120 to CD5.", "text_with_entity_marker": "We conclude that stimulation of thymocytes with pervanadate induces the recruitment of [E1]PI 3-kinase[/E1] and pp120 to [E2]CD5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PI 3-kinase", "entity_1_idx": [[87, 98]], "entity_1_idx_in_text_with_entity_marker": [91, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d205.s1776_AIMed.d205.s1776.p2", "text": "We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and pp120 to CD5.", "text_with_entity_marker": "We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3-kinase and [E1]pp120[/E1] to [E2]CD5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp120", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p0", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of [E1]UBE2I[/E1] with [E2]RAD52[/E2], UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p1", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of [E1]UBE2I[/E1] with RAD52, [E2]UBL1[/E2], p53, and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p2", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of [E1]UBE2I[/E1] with RAD52, UBL1, [E2]p53[/E2], and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p3", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of [E1]UBE2I[/E1] with RAD52, UBL1, p53, and [E2]RAD51[/E2] proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p4", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of UBE2I with [E1]RAD52[/E1], [E2]UBL1[/E2], p53, and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p5", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of UBE2I with [E1]RAD52[/E1], UBL1, [E2]p53[/E2], and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p6", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of UBE2I with [E1]RAD52[/E1], UBL1, p53, and [E2]RAD51[/E2] proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p7", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of UBE2I with RAD52, [E1]UBL1[/E1], [E2]p53[/E2], and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBL1", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p8", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of UBE2I with RAD52, [E1]UBL1[/E1], p53, and [E2]RAD51[/E2] proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBL1", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p9", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of UBE2I with RAD52, UBL1, [E1]p53[/E1], and [E2]RAD51[/E2] proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p0", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human [E1]RAD52[/E1] protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast [E2]UBC9[/E2], designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBC9", "entity_2_idx": [[118, 122]], "entity_2_idx_in_text_with_entity_marker": [131, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p1", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human [E1]RAD52[/E1] protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E2]UBE2I[/E2], that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBE2I", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p2", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human [E1]RAD52[/E1] protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with [E2]RAD52[/E2], RAD51, p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p3", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human [E1]RAD52[/E1] protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, [E2]RAD51[/E2], p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[169, 174]], "entity_2_idx_in_text_with_entity_marker": [182, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p4", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human [E1]RAD52[/E1] protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, [E2]p53[/E2], and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p5", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human [E1]RAD52[/E1] protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein [E2]UBL1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[210, 214]], "entity_2_idx_in_text_with_entity_marker": [223, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p6", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast [E1]UBC9[/E1], designated [E2]UBE2I[/E2], that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBC9", "entity_1_idx": [[118, 122]], "entity_1_idx_in_text_with_entity_marker": [122, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBE2I", "entity_2_idx": [[135, 140]], "entity_2_idx_in_text_with_entity_marker": [148, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p7", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast [E1]UBC9[/E1], designated UBE2I, that interacts with [E2]RAD52[/E2], RAD51, p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBC9", "entity_1_idx": [[118, 122]], "entity_1_idx_in_text_with_entity_marker": [122, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p8", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast [E1]UBC9[/E1], designated UBE2I, that interacts with RAD52, [E2]RAD51[/E2], p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBC9", "entity_1_idx": [[118, 122]], "entity_1_idx_in_text_with_entity_marker": [122, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[169, 174]], "entity_2_idx_in_text_with_entity_marker": [182, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p9", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast [E1]UBC9[/E1], designated UBE2I, that interacts with RAD52, RAD51, [E2]p53[/E2], and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBC9", "entity_1_idx": [[118, 122]], "entity_1_idx_in_text_with_entity_marker": [122, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p10", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast [E1]UBC9[/E1], designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein [E2]UBL1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBC9", "entity_1_idx": [[118, 122]], "entity_1_idx_in_text_with_entity_marker": [122, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[210, 214]], "entity_2_idx_in_text_with_entity_marker": [223, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p11", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E1]UBE2I[/E1], that interacts with [E2]RAD52[/E2], RAD51, p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p12", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E1]UBE2I[/E1], that interacts with RAD52, [E2]RAD51[/E2], p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[169, 174]], "entity_2_idx_in_text_with_entity_marker": [182, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p13", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E1]UBE2I[/E1], that interacts with RAD52, RAD51, [E2]p53[/E2], and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p14", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E1]UBE2I[/E1], that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein [E2]UBL1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[210, 214]], "entity_2_idx_in_text_with_entity_marker": [223, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p15", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with [E1]RAD52[/E1], [E2]RAD51[/E2], p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[169, 174]], "entity_2_idx_in_text_with_entity_marker": [182, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p16", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with [E1]RAD52[/E1], RAD51, [E2]p53[/E2], and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p17", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with [E1]RAD52[/E1], RAD51, p53, and a ubiquitin-like protein [E2]UBL1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[210, 214]], "entity_2_idx_in_text_with_entity_marker": [223, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p18", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, [E1]RAD51[/E1], [E2]p53[/E2], and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD51", "entity_1_idx": [[169, 174]], "entity_1_idx_in_text_with_entity_marker": [173, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p19", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, [E1]RAD51[/E1], p53, and a ubiquitin-like protein [E2]UBL1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD51", "entity_1_idx": [[169, 174]], "entity_1_idx_in_text_with_entity_marker": [173, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[210, 214]], "entity_2_idx_in_text_with_entity_marker": [223, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p20", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, [E1]p53[/E1], and a ubiquitin-like protein [E2]UBL1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[176, 179]], "entity_1_idx_in_text_with_entity_marker": [180, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBL1", "entity_2_idx": [[210, 214]], "entity_2_idx_in_text_with_entity_marker": [223, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1607_AIMed.d189.s1607.p0", "text": "These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.", "text_with_entity_marker": "These interactions are [E1]UBE2I[/E1]-specific, since another DNA repair-related ubiquitin-conjugating enzyme, [E2]RAD6[/E2] (UBC2), does not interact with these proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBE2I", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD6", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1607_AIMed.d189.s1607.p1", "text": "These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.", "text_with_entity_marker": "These interactions are [E1]UBE2I[/E1]-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 ([E2]UBC2[/E2]), does not interact with these proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBE2I", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBC2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1607_AIMed.d189.s1607.p2", "text": "These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.", "text_with_entity_marker": "These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, [E1]RAD6[/E1] ([E2]UBC2[/E2]), does not interact with these proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD6", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBC2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1608_AIMed.d189.s1608.p0", "text": "The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.", "text_with_entity_marker": "The interaction of [E1]UBE2I[/E1] with [E2]RAD52[/E2] is mediated by RAD52's self-association region.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1608_AIMed.d189.s1608.p1", "text": "The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.", "text_with_entity_marker": "The interaction of [E1]UBE2I[/E1] with RAD52 is mediated by [E2]RAD52[/E2]'s self-association region.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBE2I", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1608_AIMed.d189.s1608.p2", "text": "The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.", "text_with_entity_marker": "The interaction of UBE2I with [E1]RAD52[/E1] is mediated by [E2]RAD52[/E2]'s self-association region.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD52", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1609_AIMed.d189.s1609.p0", "text": "These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.", "text_with_entity_marker": "These results suggest that the [E1]RAD52[/E1]-dependent processes, cell cycle control, [E2]p53[/E2]-mediated pathway(s), and ubiquitination interact through human UBE2I.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1609_AIMed.d189.s1609.p1", "text": "These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.", "text_with_entity_marker": "These results suggest that the [E1]RAD52[/E1]-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human [E2]UBE2I[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAD52", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBE2I", "entity_2_idx": [[145, 150]], "entity_2_idx_in_text_with_entity_marker": [158, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1609_AIMed.d189.s1609.p2", "text": "These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.", "text_with_entity_marker": "These results suggest that the RAD52-dependent processes, cell cycle control, [E1]p53[/E1]-mediated pathway(s), and ubiquitination interact through human [E2]UBE2I[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBE2I", "entity_2_idx": [[145, 150]], "entity_2_idx_in_text_with_entity_marker": [158, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1320_AIMed.d156.s1320.p0", "text": "IRAK: a kinase associated with the interleukin-1 receptor.", "text_with_entity_marker": "[E1]IRAK[/E1]: a kinase associated with the [E2]interleukin-1 receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRAK", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 receptor", "entity_2_idx": [[35, 57]], "entity_2_idx_in_text_with_entity_marker": [48, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1321_AIMed.d156.s1321.p0", "text": "The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).", "text_with_entity_marker": "The pleiotropic biological activities of [E1]interleukin-1[/E1] ([E2]IL-1[/E2]) are mediated by its type I receptor (IL-1RI).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1321_AIMed.d156.s1321.p1", "text": "The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).", "text_with_entity_marker": "The pleiotropic biological activities of [E1]interleukin-1[/E1] (IL-1) are mediated by its type I receptor ([E2]IL-1RI[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin-1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1RI", "entity_2_idx": [[99, 105]], "entity_2_idx_in_text_with_entity_marker": [112, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1321_AIMed.d156.s1321.p2", "text": "The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).", "text_with_entity_marker": "The pleiotropic biological activities of interleukin-1 ([E1]IL-1[/E1]) are mediated by its type I receptor ([E2]IL-1RI[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1RI", "entity_2_idx": [[99, 105]], "entity_2_idx_in_text_with_entity_marker": [112, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1322_AIMed.d156.s1322.p0", "text": "When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).", "text_with_entity_marker": "When the ligand binds, [E1]IL-1RI[/E1] initiates a signaling cascade that results in the activation of the transcription regulator [E2]nuclear factor kappa B[/E2] (NF-kappa B).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1RI", "entity_1_idx": [[23, 29]], "entity_1_idx_in_text_with_entity_marker": [27, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nuclear factor kappa B", "entity_2_idx": [[122, 144]], "entity_2_idx_in_text_with_entity_marker": [135, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1322_AIMed.d156.s1322.p1", "text": "When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).", "text_with_entity_marker": "When the ligand binds, [E1]IL-1RI[/E1] initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B ([E2]NF-kappa B[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1RI", "entity_1_idx": [[23, 29]], "entity_1_idx_in_text_with_entity_marker": [27, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[146, 156]], "entity_2_idx_in_text_with_entity_marker": [159, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1322_AIMed.d156.s1322.p2", "text": "When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).", "text_with_entity_marker": "When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator [E1]nuclear factor kappa B[/E1] ([E2]NF-kappa B[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nuclear factor kappa B", "entity_1_idx": [[122, 144]], "entity_1_idx_in_text_with_entity_marker": [126, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[146, 156]], "entity_2_idx_in_text_with_entity_marker": [159, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1323_AIMed.d156.s1323.p0", "text": "A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.", "text_with_entity_marker": "A protein kinase designated [E1]IRAK[/E1] ([E2]IL-1[/E2] receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRAK", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1323_AIMed.d156.s1323.p1", "text": "A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.", "text_with_entity_marker": "A protein kinase designated [E1]IRAK[/E1] ([E2]IL-1 receptor-associated kinase[/E2]) was purified, and its complementary DNA was molecularly cloned.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRAK", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1 receptor-associated kinase", "entity_2_idx": [[34, 65]], "entity_2_idx_in_text_with_entity_marker": [47, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1323_AIMed.d156.s1323.p2", "text": "A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.", "text_with_entity_marker": "A protein kinase designated IRAK ([E1-E2]IL-1[/E1] receptor-associated kinase[/E2]) was purified, and its complementary DNA was molecularly cloned.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1[/E1] receptor-associated kinase", "entity_2_idx": [[34, 65]], "entity_2_idx_in_text_with_entity_marker": [41, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1324_AIMed.d156.s1324.p0", "text": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "text_with_entity_marker": "When human embryonic kidney cells (cell line 293) over-expressing [E1]IL-1RI[/E1] or HeLa cells were exposed to [E2]IL-1[/E2], IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1RI", "entity_1_idx": [[66, 72]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1324_AIMed.d156.s1324.p1", "text": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "text_with_entity_marker": "When human embryonic kidney cells (cell line 293) over-expressing [E1]IL-1RI[/E1] or HeLa cells were exposed to IL-1, [E2]IRAK[/E2] rapidly associated with the IL-1RI complex and was phosphorylated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1RI", "entity_1_idx": [[66, 72]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRAK", "entity_2_idx": [[109, 113]], "entity_2_idx_in_text_with_entity_marker": [122, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1324_AIMed.d156.s1324.p2", "text": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "text_with_entity_marker": "When human embryonic kidney cells (cell line 293) over-expressing [E1]IL-1RI[/E1] or HeLa cells were exposed to IL-1, IRAK rapidly associated with the [E2]IL-1RI[/E2] complex and was phosphorylated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1RI", "entity_1_idx": [[66, 72]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1RI", "entity_2_idx": [[142, 148]], "entity_2_idx_in_text_with_entity_marker": [155, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1324_AIMed.d156.s1324.p3", "text": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "text_with_entity_marker": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to [E1]IL-1[/E1], [E2]IRAK[/E2] rapidly associated with the IL-1RI complex and was phosphorylated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[103, 107]], "entity_1_idx_in_text_with_entity_marker": [107, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRAK", "entity_2_idx": [[109, 113]], "entity_2_idx_in_text_with_entity_marker": [122, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1324_AIMed.d156.s1324.p4", "text": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "text_with_entity_marker": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to [E1]IL-1[/E1], IRAK rapidly associated with the [E2]IL-1RI[/E2] complex and was phosphorylated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[103, 107]], "entity_1_idx_in_text_with_entity_marker": [107, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1RI", "entity_2_idx": [[142, 148]], "entity_2_idx_in_text_with_entity_marker": [155, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1324_AIMed.d156.s1324.p5", "text": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.", "text_with_entity_marker": "When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, [E1]IRAK[/E1] rapidly associated with the [E2]IL-1RI[/E2] complex and was phosphorylated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRAK", "entity_1_idx": [[109, 113]], "entity_1_idx_in_text_with_entity_marker": [113, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1RI", "entity_2_idx": [[142, 148]], "entity_2_idx_in_text_with_entity_marker": [155, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d156.s1325_AIMed.d156.s1325.p0", "text": "The primary amino acid sequence of IRAK shares similarity with that of pelle,a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.", "text_with_entity_marker": "The primary amino acid sequence of [E1]IRAK[/E1] shares similarity with that of pelle,a protein kinase that is essential for the activation of a [E2]NF-kappa B[/E2] homolog in Drosophila.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRAK", "entity_1_idx": [[35, 39]], "entity_1_idx_in_text_with_entity_marker": [39, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[136, 146]], "entity_2_idx_in_text_with_entity_marker": [149, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p0", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of [E1]SHC[/E1] and the [E2]insulin receptor substrate-1[/E2] (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHC", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[55, 83]], "entity_2_idx_in_text_with_entity_marker": [68, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p1", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of [E1]SHC[/E1] and the insulin receptor substrate-1 ([E2]IRS-1[/E2]) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHC", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p2", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of [E1]SHC[/E1] and the insulin receptor substrate-1 (IRS-1) with the [E2]insulin-like growth factor-I[/E2] (IGF-I) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHC", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I", "entity_2_idx": [[101, 129]], "entity_2_idx_in_text_with_entity_marker": [114, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p3", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of [E1]SHC[/E1] and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I ([E2]IGF-I[/E2]) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHC", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-I", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p4", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of [E1]SHC[/E1] and the insulin receptor substrate-1 (IRS-1) with the [E2]insulin-like growth factor-I (IGF-I) receptor[/E2] in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SHC", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I (IGF-I) receptor", "entity_2_idx": [[101, 146]], "entity_2_idx_in_text_with_entity_marker": [114, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p5", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the [E1]insulin receptor substrate-1[/E1] ([E2]IRS-1[/E2]) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor substrate-1", "entity_1_idx": [[55, 83]], "entity_1_idx_in_text_with_entity_marker": [59, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p6", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the [E1]insulin receptor substrate-1[/E1] (IRS-1) with the [E2]insulin-like growth factor-I[/E2] (IGF-I) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor substrate-1", "entity_1_idx": [[55, 83]], "entity_1_idx_in_text_with_entity_marker": [59, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I", "entity_2_idx": [[101, 129]], "entity_2_idx_in_text_with_entity_marker": [114, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p7", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the [E1]insulin receptor substrate-1[/E1] (IRS-1) with the insulin-like growth factor-I ([E2]IGF-I[/E2]) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor substrate-1", "entity_1_idx": [[55, 83]], "entity_1_idx_in_text_with_entity_marker": [59, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-I", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p8", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the [E1]insulin receptor substrate-1[/E1] (IRS-1) with the [E2]insulin-like growth factor-I (IGF-I) receptor[/E2] in the yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin receptor substrate-1", "entity_1_idx": [[55, 83]], "entity_1_idx_in_text_with_entity_marker": [59, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I (IGF-I) receptor", "entity_2_idx": [[101, 146]], "entity_2_idx_in_text_with_entity_marker": [114, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p9", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 ([E1]IRS-1[/E1]) with the [E2]insulin-like growth factor-I[/E2] (IGF-I) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I", "entity_2_idx": [[101, 129]], "entity_2_idx_in_text_with_entity_marker": [114, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p10", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 ([E1]IRS-1[/E1]) with the insulin-like growth factor-I ([E2]IGF-I[/E2]) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-I", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p11", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 ([E1]IRS-1[/E1]) with the [E2]insulin-like growth factor-I (IGF-I) receptor[/E2] in the yeast two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I (IGF-I) receptor", "entity_2_idx": [[101, 146]], "entity_2_idx_in_text_with_entity_marker": [114, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p12", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the [E1]insulin-like growth factor-I[/E1] ([E2]IGF-I[/E2]) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[101, 129]], "entity_1_idx_in_text_with_entity_marker": [105, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-I", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p13", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the [E1-E2]insulin-like growth factor-I[/E1] (IGF-I) receptor[/E2] in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[101, 129]], "entity_1_idx_in_text_with_entity_marker": [108, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I[/E1] (IGF-I) receptor", "entity_2_idx": [[101, 146]], "entity_2_idx_in_text_with_entity_marker": [108, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s711_AIMed.d84.s711.p14", "text": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.", "text_with_entity_marker": "Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the [E1]insulin-like growth factor-I (IGF-I) receptor[/E1][E2]IGF-I[/E2]) receptor in the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I (IGF-I) receptor", "entity_1_idx": [[101, 146]], "entity_1_idx_in_text_with_entity_marker": [105, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-I", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [159, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p0", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1-E2]insulin-like growth factor-I[/E1] receptor[/E2] (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [154, 182], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin-like growth factor-I[/E1] receptor", "entity_2_idx": [[147, 184]], "entity_2_idx_in_text_with_entity_marker": [154, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p1", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor ([E2]IGF-IR[/E2]) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[186, 192]], "entity_2_idx_in_text_with_entity_marker": [199, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p2", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor (IGF-IR) and the [E2]insulin receptor[/E2] (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[202, 218]], "entity_2_idx_in_text_with_entity_marker": [215, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p3", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor (IGF-IR) and the insulin receptor ([E2]IR[/E2]) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[220, 222]], "entity_2_idx_in_text_with_entity_marker": [233, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p4", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates [E2]p52Shc[/E2] and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p5", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E2]insulin receptor[/E2] substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[271, 287]], "entity_2_idx_in_text_with_entity_marker": [284, 300], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p6", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E2]insulin receptor substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [284, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p7", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I[/E1] receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I", "entity_1_idx": [[147, 175]], "entity_1_idx_in_text_with_entity_marker": [151, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p8", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] ([E2]IGF-IR[/E2]) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[186, 192]], "entity_2_idx_in_text_with_entity_marker": [199, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p9", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] (IGF-IR) and the [E2]insulin receptor[/E2] (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[202, 218]], "entity_2_idx_in_text_with_entity_marker": [215, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p10", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] (IGF-IR) and the insulin receptor ([E2]IR[/E2]) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[220, 222]], "entity_2_idx_in_text_with_entity_marker": [233, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p11", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] (IGF-IR) and the insulin receptor (IR) with their two known substrates [E2]p52Shc[/E2] and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p12", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E2]insulin receptor[/E2] substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[271, 287]], "entity_2_idx_in_text_with_entity_marker": [284, 300], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p13", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E2]insulin receptor substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [284, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p14", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the [E1]insulin-like growth factor-I receptor[/E1] (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin-like growth factor-I receptor", "entity_1_idx": [[147, 184]], "entity_1_idx_in_text_with_entity_marker": [151, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p15", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor ([E1]IGF-IR[/E1]) and the [E2]insulin receptor[/E2] (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[186, 192]], "entity_1_idx_in_text_with_entity_marker": [190, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[202, 218]], "entity_2_idx_in_text_with_entity_marker": [215, 231], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p16", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor ([E1]IGF-IR[/E1]) and the insulin receptor ([E2]IR[/E2]) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[186, 192]], "entity_1_idx_in_text_with_entity_marker": [190, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[220, 222]], "entity_2_idx_in_text_with_entity_marker": [233, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p17", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor ([E1]IGF-IR[/E1]) and the insulin receptor (IR) with their two known substrates [E2]p52Shc[/E2] and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[186, 192]], "entity_1_idx_in_text_with_entity_marker": [190, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p18", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor ([E1]IGF-IR[/E1]) and the insulin receptor (IR) with their two known substrates p52Shc and the [E2]insulin receptor[/E2] substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[186, 192]], "entity_1_idx_in_text_with_entity_marker": [190, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[271, 287]], "entity_2_idx_in_text_with_entity_marker": [284, 300], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p19", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor ([E1]IGF-IR[/E1]) and the insulin receptor (IR) with their two known substrates p52Shc and the [E2]insulin receptor substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[186, 192]], "entity_1_idx_in_text_with_entity_marker": [190, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [284, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p20", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor ([E1]IGF-IR[/E1]) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[186, 192]], "entity_1_idx_in_text_with_entity_marker": [190, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p21", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the [E1]insulin receptor[/E1] ([E2]IR[/E2]) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[202, 218]], "entity_1_idx_in_text_with_entity_marker": [206, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[220, 222]], "entity_2_idx_in_text_with_entity_marker": [233, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p22", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the [E1]insulin receptor[/E1] (IR) with their two known substrates [E2]p52Shc[/E2] and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin receptor", "entity_1_idx": [[202, 218]], "entity_1_idx_in_text_with_entity_marker": [206, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p23", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the [E1]insulin receptor[/E1] (IR) with their two known substrates p52Shc and the [E2]insulin receptor[/E2] substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[202, 218]], "entity_1_idx_in_text_with_entity_marker": [206, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[271, 287]], "entity_2_idx_in_text_with_entity_marker": [284, 300], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p24", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the [E1]insulin receptor[/E1] (IR) with their two known substrates p52Shc and the [E2]insulin receptor substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin receptor", "entity_1_idx": [[202, 218]], "entity_1_idx_in_text_with_entity_marker": [206, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [284, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p25", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the [E1]insulin receptor[/E1] (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin receptor", "entity_1_idx": [[202, 218]], "entity_1_idx_in_text_with_entity_marker": [206, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p26", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor ([E1]IR[/E1]) with their two known substrates [E2]p52Shc[/E2] and the insulin receptor substrate-1 (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IR", "entity_1_idx": [[220, 222]], "entity_1_idx_in_text_with_entity_marker": [224, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p27", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor ([E1]IR[/E1]) with their two known substrates p52Shc and the [E2]insulin receptor[/E2] substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[220, 222]], "entity_1_idx_in_text_with_entity_marker": [224, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[271, 287]], "entity_2_idx_in_text_with_entity_marker": [284, 300], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p28", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor ([E1]IR[/E1]) with their two known substrates p52Shc and the [E2]insulin receptor substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IR", "entity_1_idx": [[220, 222]], "entity_1_idx_in_text_with_entity_marker": [224, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [284, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p29", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor ([E1]IR[/E1]) with their two known substrates p52Shc and the insulin receptor substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IR", "entity_1_idx": [[220, 222]], "entity_1_idx_in_text_with_entity_marker": [224, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p30", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates [E1]p52Shc[/E1] and the [E2]insulin receptor[/E2] substrate-1 (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[256, 262]], "entity_1_idx_in_text_with_entity_marker": [260, 266], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[271, 287]], "entity_2_idx_in_text_with_entity_marker": [284, 300], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p31", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates [E1]p52Shc[/E1] and the [E2]insulin receptor substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[256, 262]], "entity_1_idx_in_text_with_entity_marker": [260, 266], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [284, 312], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p32", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates [E1]p52Shc[/E1] and the insulin receptor substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[256, 262]], "entity_1_idx_in_text_with_entity_marker": [260, 266], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p33", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E1-E2]insulin receptor[/E1] substrate-1[/E2] (IRS-1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[271, 287]], "entity_1_idx_in_text_with_entity_marker": [278, 294], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor[/E1] substrate-1", "entity_2_idx": [[271, 299]], "entity_2_idx_in_text_with_entity_marker": [278, 311], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p34", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E1]insulin receptor[/E1] substrate-1 ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[271, 287]], "entity_1_idx_in_text_with_entity_marker": [275, 291], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s712_AIMed.d84.s712.p35", "text": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).", "text_with_entity_marker": "Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the [E1]insulin receptor substrate-1[/E1] ([E2]IRS-1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor substrate-1", "entity_1_idx": [[271, 299]], "entity_1_idx_in_text_with_entity_marker": [275, 303], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[301, 306]], "entity_2_idx_in_text_with_entity_marker": [314, 319], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s713_AIMed.d84.s713.p0", "text": "We also mapped the specific domains of the IGF-IR and p52Shc participating in these interactions.", "text_with_entity_marker": "We also mapped the specific domains of the [E1]IGF-IR[/E1] and [E2]p52Shc[/E2] participating in these interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[54, 60]], "entity_2_idx_in_text_with_entity_marker": [67, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p0", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with [E2]p52Shc[/E2] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[128, 134]], "entity_2_idx_in_text_with_entity_marker": [141, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p1", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and [E2]IRS-1[/E2], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p2", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) [E2]p52Shc[/E2] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[151, 157]], "entity_2_idx_in_text_with_entity_marker": [164, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p3", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E2]IRS-1[/E2] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p4", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E2]IGF-IR[/E2] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p5", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E2]p52Shc[/E2], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p6", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p7", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p8", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p9", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p10", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the [E1]IGF-IR[/E1] is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[83, 89]], "entity_1_idx_in_text_with_entity_marker": [87, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p11", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and [E2]IRS-1[/E2], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p12", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) [E2]p52Shc[/E2] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[151, 157]], "entity_2_idx_in_text_with_entity_marker": [164, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p13", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and [E2]IRS-1[/E2] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p14", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the [E2]IGF-IR[/E2] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p15", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E2]p52Shc[/E2], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p16", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p17", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p18", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p19", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p20", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with [E1]p52Shc[/E1] and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p21", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) [E2]p52Shc[/E2] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[151, 157]], "entity_2_idx_in_text_with_entity_marker": [164, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p22", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and [E2]IRS-1[/E2] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p23", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the [E2]IGF-IR[/E2] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p24", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E2]p52Shc[/E2], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p25", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p26", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p27", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p28", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p29", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and [E1]IRS-1[/E1], (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p30", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and [E2]IRS-1[/E2] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p31", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the [E2]IGF-IR[/E2] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p32", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E2]p52Shc[/E2], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p33", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p34", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p35", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p36", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p37", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) [E1]p52Shc[/E1] and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[151, 157]], "entity_1_idx_in_text_with_entity_marker": [155, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p38", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the [E2]IGF-IR[/E2] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[180, 186]], "entity_2_idx_in_text_with_entity_marker": [193, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p39", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E2]p52Shc[/E2], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p40", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p41", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p42", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p43", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p44", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and [E1]IRS-1[/E1] bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p45", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E1]IGF-IR[/E1] in the NPEY-juxtamembrane motif, (iii) contrary to [E2]p52Shc[/E2], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p46", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E1]IGF-IR[/E1] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p47", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E1]IGF-IR[/E1] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p48", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E1]IGF-IR[/E1] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p49", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E1]IGF-IR[/E1] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p50", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the [E1]IGF-IR[/E1] in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[180, 186]], "entity_1_idx_in_text_with_entity_marker": [184, 190], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p51", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E1]p52Shc[/E1], [E2]IRS-1[/E2] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[238, 244]], "entity_1_idx_in_text_with_entity_marker": [242, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p52", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E1]p52Shc[/E1], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[238, 244]], "entity_1_idx_in_text_with_entity_marker": [242, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p53", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E1]p52Shc[/E1], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[238, 244]], "entity_1_idx_in_text_with_entity_marker": [242, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p54", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E1]p52Shc[/E1], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[238, 244]], "entity_1_idx_in_text_with_entity_marker": [242, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p55", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to [E1]p52Shc[/E1], IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[238, 244]], "entity_1_idx_in_text_with_entity_marker": [242, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p56", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E1]IRS-1[/E1] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E2]IGF-IR[/E2], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[246, 251]], "entity_1_idx_in_text_with_entity_marker": [250, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[338, 344]], "entity_2_idx_in_text_with_entity_marker": [351, 357], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p57", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E1]IRS-1[/E1] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[246, 251]], "entity_1_idx_in_text_with_entity_marker": [250, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p58", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E1]IRS-1[/E1] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[246, 251]], "entity_1_idx_in_text_with_entity_marker": [250, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p59", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, [E1]IRS-1[/E1] binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[246, 251]], "entity_1_idx_in_text_with_entity_marker": [250, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p60", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E1]IGF-IR[/E1], and (iv) the amino-terminal domain of [E2]p52Shc[/E2] is required for its association with the IR and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[338, 344]], "entity_1_idx_in_text_with_entity_marker": [342, 348], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[384, 390]], "entity_2_idx_in_text_with_entity_marker": [397, 403], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p61", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E1]IGF-IR[/E1], and (iv) the amino-terminal domain of p52Shc is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[338, 344]], "entity_1_idx_in_text_with_entity_marker": [342, 348], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p62", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the [E1]IGF-IR[/E1], and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[338, 344]], "entity_1_idx_in_text_with_entity_marker": [342, 348], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p63", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E1]p52Shc[/E1] is required for its association with the [E2]IR[/E2] and the IGF-IR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p52Shc", "entity_1_idx": [[384, 390]], "entity_1_idx_in_text_with_entity_marker": [388, 394], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[432, 434]], "entity_2_idx_in_text_with_entity_marker": [445, 447], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p64", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of [E1]p52Shc[/E1] is required for its association with the IR and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p52Shc", "entity_1_idx": [[384, 390]], "entity_1_idx_in_text_with_entity_marker": [388, 394], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s714_AIMed.d84.s714.p65", "text": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.", "text_with_entity_marker": "Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the [E1]IR[/E1] and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[432, 434]], "entity_1_idx_in_text_with_entity_marker": [436, 438], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[443, 449]], "entity_2_idx_in_text_with_entity_marker": [456, 462], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p0", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the [E1]IGF-IR[/E1] and the [E2]IR[/E2] share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[39, 41]], "entity_2_idx_in_text_with_entity_marker": [52, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p1", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the [E1]IGF-IR[/E1] and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, [E2]p52Shc[/E2] and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p2", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the [E1]IGF-IR[/E1] and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and [E2]IRS-1[/E2], and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p3", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the [E1]IGF-IR[/E1] and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) [E2]IRS-1[/E2] interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[175, 180]], "entity_2_idx_in_text_with_entity_marker": [188, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p4", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the [E1]IGF-IR[/E1] and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the [E2]IGF-IR[/E2] in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p5", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the [E1]IGF-IR[/E1] and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by [E2]p52Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-IR", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p6", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the [E1]IR[/E1] share at least in part the same molecular mechanism underlying their interplay with their two substrates, [E2]p52Shc[/E2] and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IR", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p7", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the [E1]IR[/E1] share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and [E2]IRS-1[/E2], and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IR", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p8", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the [E1]IR[/E1] share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) [E2]IRS-1[/E2] interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[175, 180]], "entity_2_idx_in_text_with_entity_marker": [188, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p9", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the [E1]IR[/E1] share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the [E2]IGF-IR[/E2] in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p10", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the [E1]IR[/E1] share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by [E2]p52Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p11", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, [E1]p52Shc[/E1] and [E2]IRS-1[/E2], and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p12", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, [E1]p52Shc[/E1] and IRS-1, and (ii) [E2]IRS-1[/E2] interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[175, 180]], "entity_2_idx_in_text_with_entity_marker": [188, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p13", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, [E1]p52Shc[/E1] and IRS-1, and (ii) IRS-1 interacts with the [E2]IGF-IR[/E2] in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p14", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, [E1]p52Shc[/E1] and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by [E2]p52Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p52Shc", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p15", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and [E1]IRS-1[/E1], and (ii) [E2]IRS-1[/E2] interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[175, 180]], "entity_2_idx_in_text_with_entity_marker": [188, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p16", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and [E1]IRS-1[/E1], and (ii) IRS-1 interacts with the [E2]IGF-IR[/E2] in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p17", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and [E1]IRS-1[/E1], and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by [E2]p52Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p18", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) [E1]IRS-1[/E1] interacts with the [E2]IGF-IR[/E2] in a fashion that is different from that used by p52Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[175, 180]], "entity_1_idx_in_text_with_entity_marker": [179, 184], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p19", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) [E1]IRS-1[/E1] interacts with the IGF-IR in a fashion that is different from that used by [E2]p52Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[175, 180]], "entity_1_idx_in_text_with_entity_marker": [179, 184], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s715_AIMed.d84.s715.p20", "text": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.", "text_with_entity_marker": "We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the [E1]IGF-IR[/E1] in a fashion that is different from that used by [E2]p52Shc[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-IR", "entity_1_idx": [[200, 206]], "entity_1_idx_in_text_with_entity_marker": [204, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p52Shc", "entity_2_idx": [[256, 262]], "entity_2_idx_in_text_with_entity_marker": [269, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d84.s716_AIMed.d84.s716.p0", "text": "Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the IR and the IGF-IR.", "text_with_entity_marker": "Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the [E1]IR[/E1] and the [E2]IGF-IR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[98, 100]], "entity_1_idx_in_text_with_entity_marker": [102, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-IR", "entity_2_idx": [[109, 115]], "entity_2_idx_in_text_with_entity_marker": [122, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1857_AIMed.d214.s1857.p0", "text": "Proto-oncoprotein Vav interacts with c-Cbl in activated thymocytes and peripheral T cells.", "text_with_entity_marker": "Proto-oncoprotein [E1]Vav[/E1] interacts with [E2]c-Cbl[/E2] in activated thymocytes and peripheral T cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Vav", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p0", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter [E1]c-Cbl[/E1] is rapidly tyrosine phosphorylated following stimulation through the [E2]TCR[/E2] and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[97, 100]], "entity_2_idx_in_text_with_entity_marker": [110, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p1", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter [E1]c-Cbl[/E1] is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with [E2]Src[/E2] homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Src", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p2", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter [E1]c-Cbl[/E1] is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as [E2]Grb2[/E2], Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[188, 192]], "entity_2_idx_in_text_with_entity_marker": [201, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p3", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter [E1]c-Cbl[/E1] is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, [E2]Crk[/E2], and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk", "entity_2_idx": [[194, 197]], "entity_2_idx_in_text_with_entity_marker": [207, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p4", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter [E1]c-Cbl[/E1] is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and [E2]Crk-L[/E2], which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk-L", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p5", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the [E1]TCR[/E1] and associates with [E2]Src[/E2] homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TCR", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Src", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p6", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the [E1]TCR[/E1] and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as [E2]Grb2[/E2], Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TCR", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[188, 192]], "entity_2_idx_in_text_with_entity_marker": [201, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p7", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the [E1]TCR[/E1] and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, [E2]Crk[/E2], and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TCR", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk", "entity_2_idx": [[194, 197]], "entity_2_idx_in_text_with_entity_marker": [207, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p8", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the [E1]TCR[/E1] and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and [E2]Crk-L[/E2], which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TCR", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk-L", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p9", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with [E1]Src[/E1] homology domain-2 (SH2)/SH3 domain-containing adapters such as [E2]Grb2[/E2], Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Src", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[188, 192]], "entity_2_idx_in_text_with_entity_marker": [201, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p10", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with [E1]Src[/E1] homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, [E2]Crk[/E2], and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Src", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk", "entity_2_idx": [[194, 197]], "entity_2_idx_in_text_with_entity_marker": [207, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p11", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with [E1]Src[/E1] homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and [E2]Crk-L[/E2], which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Src", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk-L", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p12", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as [E1]Grb2[/E1], [E2]Crk[/E2], and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[188, 192]], "entity_1_idx_in_text_with_entity_marker": [192, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk", "entity_2_idx": [[194, 197]], "entity_2_idx_in_text_with_entity_marker": [207, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p13", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as [E1]Grb2[/E1], Crk, and [E2]Crk-L[/E2], which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[188, 192]], "entity_1_idx_in_text_with_entity_marker": [192, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk-L", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1858_AIMed.d214.s1858.p14", "text": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, Crk, and Crk-L, which interact with guanine nucleotide exchange factors specific for the Ras family.", "text_with_entity_marker": "The molecular adapter c-Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain-2 (SH2)/SH3 domain-containing adapters such as Grb2, [E1]Crk[/E1], and [E2]Crk-L[/E2], which interact with guanine nucleotide exchange factors specific for the Ras family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Crk", "entity_1_idx": [[194, 197]], "entity_1_idx_in_text_with_entity_marker": [198, 201], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk-L", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1859_AIMed.d214.s1859.p0", "text": "This suggests that c-Cbl may link TCR activation to molecules that regulate GTP binding proteins.", "text_with_entity_marker": "This suggests that [E1]c-Cbl[/E1] may link [E2]TCR[/E2] activation to molecules that regulate GTP binding proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[34, 37]], "entity_2_idx_in_text_with_entity_marker": [47, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1860_AIMed.d214.s1860.p0", "text": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "text_with_entity_marker": "The SH2/SH3-containing protein [E1]Vav[/E1] also contains a guanine nucleotide exchange factor domain, and [E2]Vav[/E2] has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vav", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1860_AIMed.d214.s1860.p1", "text": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "text_with_entity_marker": "The SH2/SH3-containing protein [E1]Vav[/E1] also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the [E2]TCR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[217, 220]], "entity_2_idx_in_text_with_entity_marker": [230, 233], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1860_AIMed.d214.s1860.p2", "text": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "text_with_entity_marker": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and [E1]Vav[/E1] has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the [E2]TCR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[217, 220]], "entity_2_idx_in_text_with_entity_marker": [230, 233], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1861_AIMed.d214.s1861.p0", "text": "Here we show that Vav and c-Cbl form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.", "text_with_entity_marker": "Here we show that [E1]Vav[/E1] and [E2]c-Cbl[/E2] form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Vav", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[26, 31]], "entity_2_idx_in_text_with_entity_marker": [39, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1861_AIMed.d214.s1861.p1", "text": "Here we show that Vav and c-Cbl form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.", "text_with_entity_marker": "Here we show that [E1]Vav[/E1] and c-Cbl form inducible molecular complexes in [E2]TCR[/E2]-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1861_AIMed.d214.s1861.p2", "text": "Here we show that Vav and c-Cbl form inducible molecular complexes in TCR-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.", "text_with_entity_marker": "Here we show that Vav and [E1]c-Cbl[/E1] form inducible molecular complexes in [E2]TCR[/E2]-activated murine thymocytes and peripheral T cells as well as pervanadate-treated T cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1862_AIMed.d214.s1862.p0", "text": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "text_with_entity_marker": "[E1]Vav[/E1]/[E2]c-Cbl[/E2] interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Vav", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[4, 9]], "entity_2_idx_in_text_with_entity_marker": [17, 22], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1862_AIMed.d214.s1862.p1", "text": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "text_with_entity_marker": "[E1]Vav[/E1]/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor [E2]CTLA-4[/E2], in which c-Cbl is hyperphosphorylated on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTLA-4", "entity_2_idx": [[145, 151]], "entity_2_idx_in_text_with_entity_marker": [158, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1862_AIMed.d214.s1862.p2", "text": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "text_with_entity_marker": "[E1]Vav[/E1]/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which [E2]c-Cbl[/E2] is hyperphosphorylated on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1862_AIMed.d214.s1862.p3", "text": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "text_with_entity_marker": "Vav/[E1]c-Cbl[/E1] interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor [E2]CTLA-4[/E2], in which c-Cbl is hyperphosphorylated on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CTLA-4", "entity_2_idx": [[145, 151]], "entity_2_idx_in_text_with_entity_marker": [158, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1862_AIMed.d214.s1862.p4", "text": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "text_with_entity_marker": "Vav/[E1]c-Cbl[/E1] interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which [E2]c-Cbl[/E2] is hyperphosphorylated on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1862_AIMed.d214.s1862.p5", "text": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor CTLA-4, in which c-Cbl is hyperphosphorylated on tyrosine residues.", "text_with_entity_marker": "Vav/c-Cbl interactions are also detectable in freshly isolated T cells from gene-targeted mice that lack the T cell-specific inhibitory receptor [E1]CTLA-4[/E1], in which [E2]c-Cbl[/E2] is hyperphosphorylated on tyrosine residues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CTLA-4", "entity_1_idx": [[145, 151]], "entity_1_idx_in_text_with_entity_marker": [149, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1863_AIMed.d214.s1863.p0", "text": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "text_with_entity_marker": "The interaction between [E1]Vav[/E1] and [E2]c-Cbl[/E2] is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Vav", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1863_AIMed.d214.s1863.p1", "text": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "text_with_entity_marker": "The interaction between [E1]Vav[/E1] and c-Cbl is directly mediated via the SH2 domain of [E2]Vav[/E2] and is dependent on tyrosine phosphorylation of c-Cbl.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vav", "entity_2_idx": [[81, 84]], "entity_2_idx_in_text_with_entity_marker": [94, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1863_AIMed.d214.s1863.p2", "text": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "text_with_entity_marker": "The interaction between [E1]Vav[/E1] and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of [E2]c-Cbl[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1863_AIMed.d214.s1863.p3", "text": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "text_with_entity_marker": "The interaction between Vav and [E1]c-Cbl[/E1] is directly mediated via the SH2 domain of [E2]Vav[/E2] and is dependent on tyrosine phosphorylation of c-Cbl.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vav", "entity_2_idx": [[81, 84]], "entity_2_idx_in_text_with_entity_marker": [94, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1863_AIMed.d214.s1863.p4", "text": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "text_with_entity_marker": "The interaction between Vav and [E1]c-Cbl[/E1] is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of [E2]c-Cbl[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1863_AIMed.d214.s1863.p5", "text": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c-Cbl.", "text_with_entity_marker": "The interaction between Vav and c-Cbl is directly mediated via the SH2 domain of [E1]Vav[/E1] and is dependent on tyrosine phosphorylation of [E2]c-Cbl[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vav", "entity_1_idx": [[81, 84]], "entity_1_idx_in_text_with_entity_marker": [85, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1864_AIMed.d214.s1864.p0", "text": "In addition, we show that the conserved motif Y699 MTP present in c-Cbl is the binding site for the Vav SH2 domain in vitro.", "text_with_entity_marker": "In addition, we show that the conserved motif Y699 MTP present in [E1]c-Cbl[/E1] is the binding site for the [E2]Vav[/E2] SH2 domain in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[66, 71]], "entity_1_idx_in_text_with_entity_marker": [70, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vav", "entity_2_idx": [[100, 103]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1865_AIMed.d214.s1865.p0", "text": "These data imply that c-Cbl is a molecular adapter that regulates the function of Vav in thymocytes and peripheral T cells.", "text_with_entity_marker": "These data imply that [E1]c-Cbl[/E1] is a molecular adapter that regulates the function of [E2]Vav[/E2] in thymocytes and peripheral T cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vav", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d86.s728_AIMed.d86.s728.p0", "text": "For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.", "text_with_entity_marker": "For the calibration, we used two sets of proteins, the [E1]Myc[/E1]-[E2]Max[/E2]-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Myc", "entity_1_idx": [[55, 58]], "entity_1_idx_in_text_with_entity_marker": [59, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Max", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d86.s728_AIMed.d86.s728.p1", "text": "For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.", "text_with_entity_marker": "For the calibration, we used two sets of proteins, the [E1]Myc[/E1]-Max-[E2]Mxi1[/E2] helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Myc", "entity_1_idx": [[55, 58]], "entity_1_idx_in_text_with_entity_marker": [59, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mxi1", "entity_2_idx": [[63, 67]], "entity_2_idx_in_text_with_entity_marker": [76, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d86.s728_AIMed.d86.s728.p2", "text": "For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.", "text_with_entity_marker": "For the calibration, we used two sets of proteins, the Myc-[E1]Max[/E1]-[E2]Mxi1[/E2] helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Max", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Mxi1", "entity_2_idx": [[63, 67]], "entity_2_idx_in_text_with_entity_marker": [76, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1153_AIMed.d136.s1153.p0", "text": "The cytokine, designated interleukin-15 (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.", "text_with_entity_marker": "The cytokine, designated [E1]interleukin-15[/E1] ([E2]IL-15[/E2]), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-15", "entity_1_idx": [[25, 39]], "entity_1_idx_in_text_with_entity_marker": [29, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[41, 46]], "entity_2_idx_in_text_with_entity_marker": [54, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1153_AIMed.d136.s1153.p1", "text": "The cytokine, designated interleukin-15 (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.", "text_with_entity_marker": "The cytokine, designated [E1]interleukin-15[/E1] (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with [E2]IL-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-15", "entity_1_idx": [[25, 39]], "entity_1_idx_in_text_with_entity_marker": [29, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[143, 147]], "entity_2_idx_in_text_with_entity_marker": [156, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1153_AIMed.d136.s1153.p2", "text": "The cytokine, designated interleukin-15 (IL-15), is produced by a wide variety of cells and tissues and shares many biological properties with IL-2.", "text_with_entity_marker": "The cytokine, designated interleukin-15 ([E1]IL-15[/E1]), is produced by a wide variety of cells and tissues and shares many biological properties with [E2]IL-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[143, 147]], "entity_2_idx_in_text_with_entity_marker": [156, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p0", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the [E1]IL-2[/E1] receptor inhibited the biological activity of [E2]IL-15[/E2], and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[98, 103]], "entity_2_idx_in_text_with_entity_marker": [111, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p1", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the [E1]IL-2[/E1] receptor inhibited the biological activity of IL-15, and [E2]IL-15[/E2] competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p2", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the [E1]IL-2[/E1] receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with [E2]IL-2[/E2], indicating that IL-15 uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p3", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the [E1]IL-2[/E1] receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that [E2]IL-15[/E2] uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p4", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the [E1]IL-2[/E1] receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the [E2]IL-2[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[192, 196]], "entity_2_idx_in_text_with_entity_marker": [205, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p5", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the [E1]IL-2[/E1] receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the [E2]IL-2 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[192, 205]], "entity_2_idx_in_text_with_entity_marker": [205, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p6", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of [E1]IL-15[/E1], and [E2]IL-15[/E2] competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p7", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of [E1]IL-15[/E1], and IL-15 competed for binding with [E2]IL-2[/E2], indicating that IL-15 uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p8", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of [E1]IL-15[/E1], and IL-15 competed for binding with IL-2, indicating that [E2]IL-15[/E2] uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p9", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of [E1]IL-15[/E1], and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the [E2]IL-2[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[192, 196]], "entity_2_idx_in_text_with_entity_marker": [205, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p10", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of [E1]IL-15[/E1], and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the [E2]IL-2 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[192, 205]], "entity_2_idx_in_text_with_entity_marker": [205, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p11", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and [E1]IL-15[/E1] competed for binding with [E2]IL-2[/E2], indicating that IL-15 uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p12", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and [E1]IL-15[/E1] competed for binding with IL-2, indicating that [E2]IL-15[/E2] uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p13", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and [E1]IL-15[/E1] competed for binding with IL-2, indicating that IL-15 uses components of the [E2]IL-2[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[192, 196]], "entity_2_idx_in_text_with_entity_marker": [205, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p14", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and [E1]IL-15[/E1] competed for binding with IL-2, indicating that IL-15 uses components of the [E2]IL-2 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[192, 205]], "entity_2_idx_in_text_with_entity_marker": [205, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p15", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with [E1]IL-2[/E1], indicating that [E2]IL-15[/E2] uses components of the IL-2 receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-15", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p16", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with [E1]IL-2[/E1], indicating that IL-15 uses components of the [E2]IL-2[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[192, 196]], "entity_2_idx_in_text_with_entity_marker": [205, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p17", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with [E1]IL-2[/E1], indicating that IL-15 uses components of the [E2]IL-2 receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[192, 205]], "entity_2_idx_in_text_with_entity_marker": [205, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p18", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that [E1]IL-15[/E1] uses components of the [E2]IL-2[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-15", "entity_1_idx": [[163, 168]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[192, 196]], "entity_2_idx_in_text_with_entity_marker": [205, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p19", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that [E1]IL-15[/E1] uses components of the [E2]IL-2 receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-15", "entity_1_idx": [[163, 168]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[192, 205]], "entity_2_idx_in_text_with_entity_marker": [205, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d136.s1154_AIMed.d136.s1154.p20", "text": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor.", "text_with_entity_marker": "Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the [E1-E2]IL-2[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[192, 196]], "entity_1_idx_in_text_with_entity_marker": [199, 203], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2[/E1] receptor", "entity_2_idx": [[192, 205]], "entity_2_idx_in_text_with_entity_marker": [199, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1889_AIMed.d218.s1889.p0", "text": "Thrombopoietin (TPO) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets.", "text_with_entity_marker": "[E1]Thrombopoietin[/E1] ([E2]TPO[/E2]) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Thrombopoietin", "entity_1_idx": [[0, 14]], "entity_1_idx_in_text_with_entity_marker": [4, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[16, 19]], "entity_2_idx_in_text_with_entity_marker": [29, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1890_AIMed.d218.s1890.p0", "text": "We sought to characterize how TPO binds and activates its receptor, myeloproliferative leukemia virus receptor.", "text_with_entity_marker": "We sought to characterize how [E1]TPO[/E1] binds and activates its receptor, [E2]myeloproliferative leukemia virus receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TPO", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "myeloproliferative leukemia virus receptor", "entity_2_idx": [[68, 110]], "entity_2_idx_in_text_with_entity_marker": [81, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1891_AIMed.d218.s1891.p0", "text": "The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.", "text_with_entity_marker": "The [E1]erythropoietin[/E1]-like domain of [E2]TPO[/E2] (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[34, 37]], "entity_2_idx_in_text_with_entity_marker": [47, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1891_AIMed.d218.s1891.p1", "text": "The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.", "text_with_entity_marker": "The [E1]erythropoietin[/E1]-like domain of TPO (TPO1-153) has been fused to the [E2]gIII[/E2] coat protein of M13 bacteriophage.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gIII", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1891_AIMed.d218.s1891.p2", "text": "The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage.", "text_with_entity_marker": "The erythropoietin-like domain of [E1]TPO[/E1] (TPO1-153) has been fused to the [E2]gIII[/E2] coat protein of M13 bacteriophage.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TPO", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gIII", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1893_AIMed.d218.s1893.p0", "text": "Phage enzyme-linked immunosorbent assay was used to determine affinities for binding to both the TPO receptor and five anti-TPO1-153 monoclonal antibodies.", "text_with_entity_marker": "Phage enzyme-linked immunosorbent assay was used to determine affinities for binding to both the [E1]TPO[/E1] receptor and five anti-[E2]TPO1[/E2]-153 monoclonal antibodies.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TPO", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO1", "entity_2_idx": [[124, 128]], "entity_2_idx_in_text_with_entity_marker": [137, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1897_AIMed.d218.s1897.p0", "text": "In contrast, the other three monoclonal antibodies, which were effective at blocking TPO activity but did not block initial binding of TPO to its receptor, had epitopes predominantly on helix or 3.", "text_with_entity_marker": "In contrast, the other three monoclonal antibodies, which were effective at blocking [E1]TPO[/E1] activity but did not block initial binding of [E2]TPO[/E2] to its receptor, had epitopes predominantly on helix or 3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TPO", "entity_1_idx": [[85, 88]], "entity_1_idx_in_text_with_entity_marker": [89, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d218.s1898_AIMed.d218.s1898.p0", "text": "These results suggest that TPO has two distinct receptor-binding sites that function to dimerize TPO receptors in a sequential fashion.", "text_with_entity_marker": "These results suggest that [E1]TPO[/E1] has two distinct receptor-binding sites that function to dimerize [E2]TPO[/E2] receptors in a sequential fashion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TPO", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TPO", "entity_2_idx": [[97, 100]], "entity_2_idx_in_text_with_entity_marker": [110, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s899_AIMed.d107.s899.p0", "text": "A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase.", "text_with_entity_marker": "A direct interaction between [E1]G-protein beta gamma[/E1] subunits and the [E2]Raf-1 protein kinase[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "G-protein beta gamma", "entity_1_idx": [[29, 49]], "entity_1_idx_in_text_with_entity_marker": [33, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1 protein kinase", "entity_2_idx": [[67, 87]], "entity_2_idx_in_text_with_entity_marker": [80, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s900_AIMed.d107.s900.p0", "text": "Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.", "text_with_entity_marker": "[E1]Raf-1[/E1] is a serine/threonine protein kinase positioned downstream of [E2]Ras[/E2] in the mitogen-activated protein kinase cascade.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[68, 71]], "entity_2_idx_in_text_with_entity_marker": [81, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s900_AIMed.d107.s900.p1", "text": "Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.", "text_with_entity_marker": "[E1]Raf-1[/E1] is a serine/threonine protein kinase positioned downstream of Ras in the [E2]mitogen-activated protein kinase[/E2] cascade.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[79, 111]], "entity_2_idx_in_text_with_entity_marker": [92, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s900_AIMed.d107.s900.p2", "text": "Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.", "text_with_entity_marker": "Raf-1 is a serine/threonine protein kinase positioned downstream of [E1]Ras[/E1] in the [E2]mitogen-activated protein kinase[/E2] cascade.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[68, 71]], "entity_1_idx_in_text_with_entity_marker": [72, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[79, 111]], "entity_2_idx_in_text_with_entity_marker": [92, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s901_AIMed.d107.s901.p0", "text": "Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate Raf-1, we isolated a clone encoding the carboxyl-terminal half of the G beta 2 subunit of heterotrimeric G-proteins.", "text_with_entity_marker": "Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate [E1]Raf-1[/E1], we isolated a clone encoding the carboxyl-terminal half of the [E2]G beta 2 subunit[/E2] of heterotrimeric G-proteins.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta 2 subunit", "entity_2_idx": [[175, 191]], "entity_2_idx_in_text_with_entity_marker": [188, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s902_AIMed.d107.s902.p0", "text": "In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).", "text_with_entity_marker": "In vitro, purified [E1]G beta gamma[/E1] subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of [E2]Raf-1[/E2] (Raf/330).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "G beta gamma", "entity_1_idx": [[19, 31]], "entity_1_idx_in_text_with_entity_marker": [23, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s902_AIMed.d107.s902.p1", "text": "In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).", "text_with_entity_marker": "In vitro, purified [E1]G beta gamma[/E1] subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 ([E2]Raf/330[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "G beta gamma", "entity_1_idx": [[19, 31]], "entity_1_idx_in_text_with_entity_marker": [23, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf/330", "entity_2_idx": [[121, 128]], "entity_2_idx_in_text_with_entity_marker": [134, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s902_AIMed.d107.s902.p2", "text": "In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).", "text_with_entity_marker": "In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of [E1]Raf-1[/E1] ([E2]Raf/330[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[114, 119]], "entity_1_idx_in_text_with_entity_marker": [118, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf/330", "entity_2_idx": [[121, 128]], "entity_2_idx_in_text_with_entity_marker": [134, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s903_AIMed.d107.s903.p0", "text": "Binding assays with truncation mutants of GST-Raf indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with G beta gamma.", "text_with_entity_marker": "Binding assays with truncation mutants of GST-[E1]Raf[/E1] indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with [E2]G beta gamma[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[161, 173]], "entity_2_idx_in_text_with_entity_marker": [174, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p0", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of [E1]beta-adrenergic receptor kinase[/E1] ([E2]beta ARK[/E2]) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-adrenergic receptor kinase", "entity_1_idx": [[53, 84]], "entity_1_idx_in_text_with_entity_marker": [57, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta ARK", "entity_2_idx": [[86, 94]], "entity_2_idx_in_text_with_entity_marker": [99, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p1", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of [E1]beta-adrenergic receptor kinase[/E1] (beta ARK) blocked the binding of [E2]G beta gamma[/E2] to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-adrenergic receptor kinase", "entity_1_idx": [[53, 84]], "entity_1_idx_in_text_with_entity_marker": [57, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[119, 131]], "entity_2_idx_in_text_with_entity_marker": [132, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p2", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of [E1]beta-adrenergic receptor kinase[/E1] (beta ARK) blocked the binding of G beta gamma to [E2]Raf/330[/E2]; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-adrenergic receptor kinase", "entity_1_idx": [[53, 84]], "entity_1_idx_in_text_with_entity_marker": [57, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf/330", "entity_2_idx": [[135, 142]], "entity_2_idx_in_text_with_entity_marker": [148, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p3", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of [E1]beta-adrenergic receptor kinase[/E1] (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the [E2]Raf-1[/E2]-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-adrenergic receptor kinase", "entity_1_idx": [[53, 84]], "entity_1_idx_in_text_with_entity_marker": [57, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p4", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of [E1]beta-adrenergic receptor kinase[/E1] (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, [E2]Ras[/E2] and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-adrenergic receptor kinase", "entity_1_idx": [[53, 84]], "entity_1_idx_in_text_with_entity_marker": [57, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p5", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase ([E1]beta ARK[/E1]) blocked the binding of [E2]G beta gamma[/E2] to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta ARK", "entity_1_idx": [[86, 94]], "entity_1_idx_in_text_with_entity_marker": [90, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[119, 131]], "entity_2_idx_in_text_with_entity_marker": [132, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p6", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase ([E1]beta ARK[/E1]) blocked the binding of G beta gamma to [E2]Raf/330[/E2]; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta ARK", "entity_1_idx": [[86, 94]], "entity_1_idx_in_text_with_entity_marker": [90, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf/330", "entity_2_idx": [[135, 142]], "entity_2_idx_in_text_with_entity_marker": [148, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p7", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase ([E1]beta ARK[/E1]) blocked the binding of G beta gamma to Raf/330; however, the [E2]Raf-1[/E2]-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta ARK", "entity_1_idx": [[86, 94]], "entity_1_idx_in_text_with_entity_marker": [90, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p8", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase ([E1]beta ARK[/E1]) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, [E2]Ras[/E2] and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta ARK", "entity_1_idx": [[86, 94]], "entity_1_idx_in_text_with_entity_marker": [90, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p9", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of [E1]G beta gamma[/E1] to [E2]Raf/330[/E2]; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "G beta gamma", "entity_1_idx": [[119, 131]], "entity_1_idx_in_text_with_entity_marker": [123, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf/330", "entity_2_idx": [[135, 142]], "entity_2_idx_in_text_with_entity_marker": [148, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p10", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of [E1]G beta gamma[/E1] to Raf/330; however, the [E2]Raf-1[/E2]-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G beta gamma", "entity_1_idx": [[119, 131]], "entity_1_idx_in_text_with_entity_marker": [123, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p11", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of [E1]G beta gamma[/E1] to Raf/330; however, the Raf-1-binding proteins, [E2]Ras[/E2] and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G beta gamma", "entity_1_idx": [[119, 131]], "entity_1_idx_in_text_with_entity_marker": [123, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p12", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to [E1]Raf/330[/E1]; however, the [E2]Raf-1[/E2]-binding proteins, Ras and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf/330", "entity_1_idx": [[135, 142]], "entity_1_idx_in_text_with_entity_marker": [139, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p13", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to [E1]Raf/330[/E1]; however, the Raf-1-binding proteins, [E2]Ras[/E2] and 14-3-3, had no effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf/330", "entity_1_idx": [[135, 142]], "entity_1_idx_in_text_with_entity_marker": [139, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s904_AIMed.d107.s904.p14", "text": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.", "text_with_entity_marker": "In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the [E1]Raf-1[/E1]-binding proteins, [E2]Ras[/E2] and 14-3-3, had no effect.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[157, 162]], "entity_1_idx_in_text_with_entity_marker": [161, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s905_AIMed.d107.s905.p0", "text": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "text_with_entity_marker": "Scatchard analysis of in vitro binding between [E1]Raf/330[/E1] and [E2]G beta gamma[/E2] revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf/330", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[59, 71]], "entity_2_idx_in_text_with_entity_marker": [72, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s905_AIMed.d107.s905.p1", "text": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "text_with_entity_marker": "Scatchard analysis of in vitro binding between [E1]Raf/330[/E1] and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between [E2]G beta gamma[/E2] and beta ARK (Kd = 87 +/- 24 nM).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf/330", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[159, 171]], "entity_2_idx_in_text_with_entity_marker": [172, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s905_AIMed.d107.s905.p2", "text": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "text_with_entity_marker": "Scatchard analysis of in vitro binding between [E1]Raf/330[/E1] and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and [E2]beta ARK[/E2] (Kd = 87 +/- 24 nM).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf/330", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta ARK", "entity_2_idx": [[176, 184]], "entity_2_idx_in_text_with_entity_marker": [189, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s905_AIMed.d107.s905.p3", "text": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "text_with_entity_marker": "Scatchard analysis of in vitro binding between Raf/330 and [E1]G beta gamma[/E1] revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between [E2]G beta gamma[/E2] and beta ARK (Kd = 87 +/- 24 nM).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G beta gamma", "entity_1_idx": [[59, 71]], "entity_1_idx_in_text_with_entity_marker": [63, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[159, 171]], "entity_2_idx_in_text_with_entity_marker": [172, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s905_AIMed.d107.s905.p4", "text": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "text_with_entity_marker": "Scatchard analysis of in vitro binding between Raf/330 and [E1]G beta gamma[/E1] revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and [E2]beta ARK[/E2] (Kd = 87 +/- 24 nM).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G beta gamma", "entity_1_idx": [[59, 71]], "entity_1_idx_in_text_with_entity_marker": [63, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta ARK", "entity_2_idx": [[176, 184]], "entity_2_idx_in_text_with_entity_marker": [189, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s905_AIMed.d107.s905.p5", "text": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).", "text_with_entity_marker": "Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between [E1]G beta gamma[/E1] and [E2]beta ARK[/E2] (Kd = 87 +/- 24 nM).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "G beta gamma", "entity_1_idx": [[159, 171]], "entity_1_idx_in_text_with_entity_marker": [163, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta ARK", "entity_2_idx": [[176, 184]], "entity_2_idx_in_text_with_entity_marker": [189, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s906_AIMed.d107.s906.p0", "text": "The formation of native heterotrimeric G alpha beta gamma complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of Raf/330, with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.", "text_with_entity_marker": "The formation of native heterotrimeric [E1]G alpha beta gamma[/E1] complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of [E2]Raf/330[/E2], with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G alpha beta gamma", "entity_1_idx": [[39, 57]], "entity_1_idx_in_text_with_entity_marker": [43, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf/330", "entity_2_idx": [[173, 180]], "entity_2_idx_in_text_with_entity_marker": [186, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s907_AIMed.d107.s907.p0", "text": "In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.", "text_with_entity_marker": "In vivo complexes of [E1]Raf-1[/E1] and [E2]G beta gamma[/E2] were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta gamma", "entity_2_idx": [[31, 43]], "entity_2_idx_in_text_with_entity_marker": [44, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s907_AIMed.d107.s907.p1", "text": "In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.", "text_with_entity_marker": "In vivo complexes of [E1]Raf-1[/E1] and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged [E2]G beta 2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta 2", "entity_2_idx": [[130, 138]], "entity_2_idx_in_text_with_entity_marker": [143, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d107.s907_AIMed.d107.s907.p2", "text": "In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.", "text_with_entity_marker": "In vivo complexes of Raf-1 and [E1]G beta gamma[/E1] were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged [E2]G beta 2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G beta gamma", "entity_1_idx": [[31, 43]], "entity_1_idx_in_text_with_entity_marker": [35, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G beta 2", "entity_2_idx": [[130, 138]], "entity_2_idx_in_text_with_entity_marker": [143, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p0", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human [E1]CC chemokine liver-expressed chemokine[/E1]/[E2]CCL16[/E2] is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CC chemokine liver-expressed chemokine", "entity_1_idx": [[6, 44]], "entity_1_idx_in_text_with_entity_marker": [10, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[45, 50]], "entity_2_idx_in_text_with_entity_marker": [58, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p1", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human [E1]CC chemokine liver-expressed chemokine[/E1]/CCL16 is a functional ligand for [E2]CCR1[/E2], CCR2 and CCR5, and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CC chemokine liver-expressed chemokine", "entity_1_idx": [[6, 44]], "entity_1_idx_in_text_with_entity_marker": [10, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p2", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human [E1]CC chemokine liver-expressed chemokine[/E1]/CCL16 is a functional ligand for CCR1, [E2]CCR2[/E2] and CCR5, and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CC chemokine liver-expressed chemokine", "entity_1_idx": [[6, 44]], "entity_1_idx_in_text_with_entity_marker": [10, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[84, 88]], "entity_2_idx_in_text_with_entity_marker": [97, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p3", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human [E1]CC chemokine liver-expressed chemokine[/E1]/CCL16 is a functional ligand for CCR1, CCR2 and [E2]CCR5[/E2], and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CC chemokine liver-expressed chemokine", "entity_1_idx": [[6, 44]], "entity_1_idx_in_text_with_entity_marker": [10, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p4", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human CC chemokine liver-expressed chemokine/[E1]CCL16[/E1] is a functional ligand for [E2]CCR1[/E2], CCR2 and CCR5, and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCL16", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p5", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human CC chemokine liver-expressed chemokine/[E1]CCL16[/E1] is a functional ligand for CCR1, [E2]CCR2[/E2] and CCR5, and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCL16", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[84, 88]], "entity_2_idx_in_text_with_entity_marker": [97, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p6", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human CC chemokine liver-expressed chemokine/[E1]CCL16[/E1] is a functional ligand for CCR1, CCR2 and [E2]CCR5[/E2], and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCL16", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p7", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for [E1]CCR1[/E1], [E2]CCR2[/E2] and CCR5, and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[84, 88]], "entity_2_idx_in_text_with_entity_marker": [97, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p8", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for [E1]CCR1[/E1], CCR2 and [E2]CCR5[/E2], and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s481_AIMed.d55.s481.p9", "text": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.", "text_with_entity_marker": "Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, [E1]CCR2[/E1] and [E2]CCR5[/E2], and constitutively expressed by hepatocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR2", "entity_1_idx": [[84, 88]], "entity_1_idx_in_text_with_entity_marker": [88, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s482_AIMed.d55.s482.p0", "text": "Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] ([E2]LEC[/E2])/CCL16 is a human CC chemokine selectively expressed in the liver.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEC", "entity_2_idx": [[27, 30]], "entity_2_idx_in_text_with_entity_marker": [40, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s482_AIMed.d55.s482.p1", "text": "Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] (LEC)/[E2]CCL16[/E2] is a human CC chemokine selectively expressed in the liver.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s482_AIMed.d55.s482.p2", "text": "Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.", "text_with_entity_marker": "Liver-expressed chemokine ([E1]LEC[/E1])/[E2]CCL16[/E2] is a human CC chemokine selectively expressed in the liver.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s484_AIMed.d55.s484.p0", "text": "At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.", "text_with_entity_marker": "At relatively high concentrations, [E1]LEC[/E1] induced calcium mobilization and chemotaxis via [E2]CCR1[/E2] and CCR2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s484_AIMed.d55.s484.p1", "text": "At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.", "text_with_entity_marker": "At relatively high concentrations, [E1]LEC[/E1] induced calcium mobilization and chemotaxis via CCR1 and [E2]CCR2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s484_AIMed.d55.s484.p2", "text": "At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.", "text_with_entity_marker": "At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via [E1]CCR1[/E1] and [E2]CCR2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s485_AIMed.d55.s485.p0", "text": "LEC also induced calcium mobilization, but marginal chemotaxis via CCR5.", "text_with_entity_marker": "[E1]LEC[/E1] also induced calcium mobilization, but marginal chemotaxis via [E2]CCR5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s486_AIMed.d55.s486.p0", "text": "Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.", "text_with_entity_marker": "Consistently, [E1]LEC[/E1] was found to bind to [E2]CCR1[/E2], CCR2 and CCR5 with relatively low affinities.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[39, 43]], "entity_2_idx_in_text_with_entity_marker": [52, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s486_AIMed.d55.s486.p1", "text": "Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.", "text_with_entity_marker": "Consistently, [E1]LEC[/E1] was found to bind to CCR1, [E2]CCR2[/E2] and CCR5 with relatively low affinities.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s486_AIMed.d55.s486.p2", "text": "Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.", "text_with_entity_marker": "Consistently, [E1]LEC[/E1] was found to bind to CCR1, CCR2 and [E2]CCR5[/E2] with relatively low affinities.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[54, 58]], "entity_2_idx_in_text_with_entity_marker": [67, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s486_AIMed.d55.s486.p3", "text": "Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.", "text_with_entity_marker": "Consistently, LEC was found to bind to [E1]CCR1[/E1], [E2]CCR2[/E2] and CCR5 with relatively low affinities.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s486_AIMed.d55.s486.p4", "text": "Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.", "text_with_entity_marker": "Consistently, LEC was found to bind to [E1]CCR1[/E1], CCR2 and [E2]CCR5[/E2] with relatively low affinities.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[54, 58]], "entity_2_idx_in_text_with_entity_marker": [67, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s486_AIMed.d55.s486.p5", "text": "Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.", "text_with_entity_marker": "Consistently, LEC was found to bind to CCR1, [E1]CCR2[/E1] and [E2]CCR5[/E2] with relatively low affinities.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR2", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[54, 58]], "entity_2_idx_in_text_with_entity_marker": [67, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s487_AIMed.d55.s487.p0", "text": "The binding of LEC to CCR8 was much less significant.", "text_with_entity_marker": "The binding of [E1]LEC[/E1] to [E2]CCR8[/E2] was much less significant.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s488_AIMed.d55.s488.p0", "text": "In spite of its binding to CCR5, LEC was unable to inhibit infection of an R5-type HIV-1 to activated human peripheral blood mononuclear cells even at high concentrations.", "text_with_entity_marker": "In spite of its binding to [E1]CCR5[/E1], [E2]LEC[/E2] was unable to inhibit infection of an R5-type HIV-1 to activated human peripheral blood mononuclear cells even at high concentrations.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR5", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEC", "entity_2_idx": [[33, 36]], "entity_2_idx_in_text_with_entity_marker": [46, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s492_AIMed.d55.s492.p0", "text": "Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "text_with_entity_marker": "Taken together, [E1]LEC[/E1] is a new low-affinity functional ligand for [E2]CCR1[/E2], CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[64, 68]], "entity_2_idx_in_text_with_entity_marker": [77, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s492_AIMed.d55.s492.p1", "text": "Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "text_with_entity_marker": "Taken together, [E1]LEC[/E1] is a new low-affinity functional ligand for CCR1, [E2]CCR2[/E2] and CCR5, and is constitutively expressed by liver parenchymal cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s492_AIMed.d55.s492.p2", "text": "Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "text_with_entity_marker": "Taken together, [E1]LEC[/E1] is a new low-affinity functional ligand for CCR1, CCR2 and [E2]CCR5[/E2], and is constitutively expressed by liver parenchymal cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s492_AIMed.d55.s492.p3", "text": "Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "text_with_entity_marker": "Taken together, LEC is a new low-affinity functional ligand for [E1]CCR1[/E1], [E2]CCR2[/E2] and CCR5, and is constitutively expressed by liver parenchymal cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR2", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s492_AIMed.d55.s492.p4", "text": "Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "text_with_entity_marker": "Taken together, LEC is a new low-affinity functional ligand for [E1]CCR1[/E1], CCR2 and [E2]CCR5[/E2], and is constitutively expressed by liver parenchymal cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d55.s492_AIMed.d55.s492.p5", "text": "Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.", "text_with_entity_marker": "Taken together, LEC is a new low-affinity functional ligand for CCR1, [E1]CCR2[/E1] and [E2]CCR5[/E2], and is constitutively expressed by liver parenchymal cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR2", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR5", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s852_AIMed.d101.s852.p0", "text": "The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.", "text_with_entity_marker": "The bZIP domains of [E1]Fos[/E1] and [E2]Jun[/E2] mediate a physical association with the TATA box-binding protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s852_AIMed.d101.s852.p1", "text": "The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.", "text_with_entity_marker": "The bZIP domains of [E1]Fos[/E1] and Jun mediate a physical association with the [E2]TATA box-binding protein[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[72, 96]], "entity_2_idx_in_text_with_entity_marker": [85, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s852_AIMed.d101.s852.p2", "text": "The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.", "text_with_entity_marker": "The bZIP domains of Fos and [E1]Jun[/E1] mediate a physical association with the [E2]TATA box-binding protein[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jun", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[72, 96]], "entity_2_idx_in_text_with_entity_marker": [85, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s853_AIMed.d101.s853.p0", "text": "Fos and Jun oncoproteins form a complex that regulates transcription from promoters containing AP-1 binding sites.", "text_with_entity_marker": "[E1]Fos[/E1] and [E2]Jun[/E2] oncoproteins form a complex that regulates transcription from promoters containing AP-1 binding sites.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[8, 11]], "entity_2_idx_in_text_with_entity_marker": [21, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p0", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of [E1]c-Fos[/E1] and [E2]c-Jun[/E2] proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[25, 30]], "entity_2_idx_in_text_with_entity_marker": [38, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p1", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of [E1]c-Fos[/E1] and c-Jun proteins to interact directly with the [E2]TATA box-binding protein[/E2] (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[70, 94]], "entity_2_idx_in_text_with_entity_marker": [83, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p2", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of [E1]c-Fos[/E1] and c-Jun proteins to interact directly with the TATA box-binding protein ([E2]TBP[/E2]), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p3", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of c-Fos and [E1]c-Jun[/E1] proteins to interact directly with the [E2]TATA box-binding protein[/E2] (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[70, 94]], "entity_2_idx_in_text_with_entity_marker": [83, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p4", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of c-Fos and [E1]c-Jun[/E1] proteins to interact directly with the TATA box-binding protein ([E2]TBP[/E2]), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p5", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of c-Fos and c-Jun proteins to interact directly with the [E1]TATA box-binding protein[/E1] ([E2]TBP[/E2]), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA box-binding protein", "entity_1_idx": [[70, 94]], "entity_1_idx_in_text_with_entity_marker": [74, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p0", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both [E1]c-Fos[/E1] and [E2]c-Jun[/E2] bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[97, 102]], "entity_2_idx_in_text_with_entity_marker": [110, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p1", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both [E1]c-Fos[/E1] and c-Jun bind specifically and stably to [E2]TBP[/E2].Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p2", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both [E1]c-Fos[/E1] and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of [E2]c-Fos[/E2] and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[229, 234]], "entity_2_idx_in_text_with_entity_marker": [242, 247], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p3", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both [E1]c-Fos[/E1] and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and [E2]c-Jun[/E2] are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p4", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both [E1]c-Fos[/E1] and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p5", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and [E1]c-Jun[/E1] bind specifically and stably to [E2]TBP[/E2].Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p6", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and [E1]c-Jun[/E1] bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of [E2]c-Fos[/E2] and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[229, 234]], "entity_2_idx_in_text_with_entity_marker": [242, 247], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p7", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and [E1]c-Jun[/E1] bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and [E2]c-Jun[/E2] are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p8", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and [E1]c-Jun[/E1] bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p9", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to [E1]TBP[/E1].Mutational analysis demonstrates that both the basic region and leucine zipper domains of [E2]c-Fos[/E2] and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[229, 234]], "entity_2_idx_in_text_with_entity_marker": [242, 247], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p10", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to [E1]TBP[/E1].Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and [E2]c-Jun[/E2] are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p11", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to [E1]TBP[/E1].Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p12", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of [E1]c-Fos[/E1] and [E2]c-Jun[/E2] are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[229, 234]], "entity_1_idx_in_text_with_entity_marker": [233, 238], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p13", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of [E1]c-Fos[/E1] and c-Jun are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[229, 234]], "entity_1_idx_in_text_with_entity_marker": [233, 238], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p14", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and [E1]c-Jun[/E1] are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[239, 244]], "entity_1_idx_in_text_with_entity_marker": [243, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p0", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of [E1]TBP[/E1], previously shown to be the binding site for the viral activator protein [E2]E1A[/E2], interacts with c-Fos and c-Jun proteins.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p1", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of [E1]TBP[/E1], previously shown to be the binding site for the viral activator protein E1A, interacts with [E2]c-Fos[/E2] and c-Jun proteins.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p2", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of [E1]TBP[/E1], previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and [E2]c-Jun[/E2] proteins.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[167, 172]], "entity_2_idx_in_text_with_entity_marker": [180, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p3", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein [E1]E1A[/E1], interacts with [E2]c-Fos[/E2] and c-Jun proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E1A", "entity_1_idx": [[137, 140]], "entity_1_idx_in_text_with_entity_marker": [141, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p4", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein [E1]E1A[/E1], interacts with c-Fos and [E2]c-Jun[/E2] proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E1A", "entity_1_idx": [[137, 140]], "entity_1_idx_in_text_with_entity_marker": [141, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[167, 172]], "entity_2_idx_in_text_with_entity_marker": [180, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p5", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with [E1]c-Fos[/E1] and [E2]c-Jun[/E2] proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[157, 162]], "entity_1_idx_in_text_with_entity_marker": [161, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[167, 172]], "entity_2_idx_in_text_with_entity_marker": [180, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s858_AIMed.d101.s858.p0", "text": "We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.", "text_with_entity_marker": "We propose that [E1]c-Fos[/E1] and [E2]c-Jun[/E2] proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[26, 31]], "entity_2_idx_in_text_with_entity_marker": [39, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s858_AIMed.d101.s858.p1", "text": "We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.", "text_with_entity_marker": "We propose that [E1]c-Fos[/E1] and c-Jun proteins function as transcriptional activators, in part by recruiting [E2]TBP[/E2] to form complexes to initiate RNA synthesis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s858_AIMed.d101.s858.p2", "text": "We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.", "text_with_entity_marker": "We propose that c-Fos and [E1]c-Jun[/E1] proteins function as transcriptional activators, in part by recruiting [E2]TBP[/E2] to form complexes to initiate RNA synthesis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d139.s1171_AIMed.d139.s1171.p0", "text": "Spectrin cagliari. an Ala-->Gly substitution in helix 1 of beta spectrin repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer.", "text_with_entity_marker": "[E1]Spectrin cagliari[/E1]. an Ala-->Gly substitution in helix 1 of [E2]beta spectrin[/E2] repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Spectrin cagliari", "entity_1_idx": [[0, 17]], "entity_1_idx_in_text_with_entity_marker": [4, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta spectrin", "entity_2_idx": [[59, 72]], "entity_2_idx_in_text_with_entity_marker": [72, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d139.s1173_AIMed.d139.s1173.p0", "text": "The self-association site appears to be formed by interactions between helices 1 and 2 of beta spectrin repeat 17 of one dimer with helix 3 of alpha spectrin repeat 1 of the other dimer to form two combined alpha-beta triple-helical segments.", "text_with_entity_marker": "The self-association site appears to be formed by interactions between helices 1 and 2 of [E1]beta spectrin[/E1] repeat 17 of one dimer with helix 3 of [E2]alpha spectrin[/E2] repeat 1 of the other dimer to form two combined alpha-beta triple-helical segments.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "beta spectrin", "entity_1_idx": [[90, 103]], "entity_1_idx_in_text_with_entity_marker": [94, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha spectrin", "entity_2_idx": [[143, 157]], "entity_2_idx_in_text_with_entity_marker": [156, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d139.s1177_AIMed.d139.s1177.p0", "text": "Following linkage studies which were most consistent with a beta spectrin gene mutation, a nucleotide change was identified in codon 2018, resulting in an Ala-->Gly substitution in the first helical domain of beta spectrin repeat 17.", "text_with_entity_marker": "Following linkage studies which were most consistent with a [E1]beta spectrin[/E1] gene mutation, a nucleotide change was identified in codon 2018, resulting in an Ala-->Gly substitution in the first helical domain of [E2]beta spectrin[/E2] repeat 17.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta spectrin", "entity_1_idx": [[60, 73]], "entity_1_idx_in_text_with_entity_marker": [64, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta spectrin", "entity_2_idx": [[209, 222]], "entity_2_idx_in_text_with_entity_marker": [222, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1675_AIMed.d197.s1675.p0", "text": "Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.", "text_with_entity_marker": "Analysis of the human [E1]interleukin-6[/E1]/human [E2]interleukin-6[/E2] receptor binding interface at the amino acid level: proposed mechanism of interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[22, 35]], "entity_1_idx_in_text_with_entity_marker": [26, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-6", "entity_2_idx": [[42, 55]], "entity_2_idx_in_text_with_entity_marker": [55, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1675_AIMed.d197.s1675.p1", "text": "Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.", "text_with_entity_marker": "Analysis of the human [E1]interleukin-6[/E1]/human [E2]interleukin-6 receptor[/E2] binding interface at the amino acid level: proposed mechanism of interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[22, 35]], "entity_1_idx_in_text_with_entity_marker": [26, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-6 receptor", "entity_2_idx": [[42, 64]], "entity_2_idx_in_text_with_entity_marker": [55, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1675_AIMed.d197.s1675.p2", "text": "Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.", "text_with_entity_marker": "Analysis of the human interleukin-6/human [E1-E2]interleukin-6[/E1] receptor[/E2] binding interface at the amino acid level: proposed mechanism of interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [49, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-6[/E1] receptor", "entity_2_idx": [[42, 64]], "entity_2_idx_in_text_with_entity_marker": [49, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p0", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] ([E2]IL-6[/E2]) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[39, 43]], "entity_2_idx_in_text_with_entity_marker": [52, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p1", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] (IL-6) and [E2]IL-6[/E2] receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p2", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] (IL-6) and [E2]IL-6 receptor[/E2] (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[49, 62]], "entity_2_idx_in_text_with_entity_marker": [62, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p3", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] (IL-6) and IL-6 receptor ([E2]IL-6R[/E2]) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p4", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the [E2]IL-6[/E2] signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p5", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 ([E1]IL-6[/E1]) and [E2]IL-6[/E2] receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p6", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 ([E1]IL-6[/E1]) and [E2]IL-6 receptor[/E2] (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[49, 62]], "entity_2_idx_in_text_with_entity_marker": [62, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p7", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 ([E1]IL-6[/E1]) and IL-6 receptor ([E2]IL-6R[/E2]) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p8", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 ([E1]IL-6[/E1]) and IL-6 receptor (IL-6R) is the initial and most specific step in the [E2]IL-6[/E2] signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p9", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and [E1-E2]IL-6[/E1] receptor[/E2] (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6[/E1] receptor", "entity_2_idx": [[49, 62]], "entity_2_idx_in_text_with_entity_marker": [56, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p10", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and [E1]IL-6[/E1] receptor ([E2]IL-6R[/E2]) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p11", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and [E1]IL-6[/E1] receptor (IL-6R) is the initial and most specific step in the [E2]IL-6[/E2] signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p12", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and [E1]IL-6 receptor[/E1] ([E2]IL-6R[/E2]) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6 receptor", "entity_1_idx": [[49, 62]], "entity_1_idx_in_text_with_entity_marker": [53, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p13", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and [E1]IL-6 receptor[/E1] (IL-6R) is the initial and most specific step in the [E2]IL-6[/E2] signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6 receptor", "entity_1_idx": [[49, 62]], "entity_1_idx_in_text_with_entity_marker": [53, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p14", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and IL-6 receptor ([E1]IL-6R[/E1]) is the initial and most specific step in the [E2]IL-6[/E2] signaling pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[64, 69]], "entity_1_idx_in_text_with_entity_marker": [68, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1678_AIMed.d197.s1678.p0", "text": "We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.", "text_with_entity_marker": "We studied the human [E1]IL-6[/E1] ([E2]hIL-6[/E2])/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1678_AIMed.d197.s1678.p1", "text": "We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.", "text_with_entity_marker": "We studied the human [E1]IL-6[/E1] (hIL-6)/[E2]hIL-6R[/E2] binding interface by a combination of molecular modelling and site-directed mutagenesis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6R", "entity_2_idx": [[34, 40]], "entity_2_idx_in_text_with_entity_marker": [47, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1678_AIMed.d197.s1678.p2", "text": "We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.", "text_with_entity_marker": "We studied the human IL-6 ([E1]hIL-6[/E1])/[E2]hIL-6R[/E2] binding interface by a combination of molecular modelling and site-directed mutagenesis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hIL-6", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6R", "entity_2_idx": [[34, 40]], "entity_2_idx_in_text_with_entity_marker": [47, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1681_AIMed.d197.s1681.p0", "text": "Following this hypothesis, we altered in hIL-6 and hIL-6R residues predicted to reside in the contact region and to interact with each other.", "text_with_entity_marker": "Following this hypothesis, we altered in [E1]hIL-6[/E1] and [E2]hIL-6R[/E2] residues predicted to reside in the contact region and to interact with each other.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hIL-6", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6R", "entity_2_idx": [[51, 57]], "entity_2_idx_in_text_with_entity_marker": [64, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1682_AIMed.d197.s1682.p0", "text": "We studied the capacity of these mutants to form an IL-6/IL-6R complex and their ability to transduce the signal.", "text_with_entity_marker": "We studied the capacity of these mutants to form an [E1]IL-6[/E1]/[E2]IL-6R[/E2] complex and their ability to transduce the signal.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[57, 62]], "entity_2_idx_in_text_with_entity_marker": [70, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1155_AIMed.d137.s1155.p0", "text": "The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP.", "text_with_entity_marker": "The POU domains of the [E1]Oct1[/E1] and [E2]Oct2[/E2] transcription factors mediate specific interaction with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct1", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1155_AIMed.d137.s1155.p1", "text": "The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP.", "text_with_entity_marker": "The POU domains of the [E1]Oct1[/E1] and Oct2 transcription factors mediate specific interaction with [E2]TBP[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oct1", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[93, 96]], "entity_2_idx_in_text_with_entity_marker": [106, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1155_AIMed.d137.s1155.p2", "text": "The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP.", "text_with_entity_marker": "The POU domains of the Oct1 and [E1]Oct2[/E1] transcription factors mediate specific interaction with [E2]TBP[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oct2", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[93, 96]], "entity_2_idx_in_text_with_entity_marker": [106, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1156_AIMed.d137.s1156.p0", "text": "We had previously shown that the ubiquitous Oct1 and the lymphoid-specific Oct2 transcription factors stimulate transcription at the level of stable preinitiation complex formation.", "text_with_entity_marker": "We had previously shown that the ubiquitous [E1]Oct1[/E1] and the lymphoid-specific [E2]Oct2[/E2] transcription factors stimulate transcription at the level of stable preinitiation complex formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct1", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[75, 79]], "entity_2_idx_in_text_with_entity_marker": [88, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1157_AIMed.d137.s1157.p0", "text": "We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the TATA box binding protein component of the TFIID factor.", "text_with_entity_marker": "We have therefore investigated whether the octamer binding proteins might physically interact with [E1]TBP[/E1], the [E2]TATA box binding protein[/E2] component of the TFIID factor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[99, 102]], "entity_1_idx_in_text_with_entity_marker": [103, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box binding protein", "entity_2_idx": [[108, 132]], "entity_2_idx_in_text_with_entity_marker": [121, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1157_AIMed.d137.s1157.p1", "text": "We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the TATA box binding protein component of the TFIID factor.", "text_with_entity_marker": "We have therefore investigated whether the octamer binding proteins might physically interact with [E1]TBP[/E1], the TATA box binding protein component of the [E2]TFIID[/E2] factor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[99, 102]], "entity_1_idx_in_text_with_entity_marker": [103, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1157_AIMed.d137.s1157.p2", "text": "We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the TATA box binding protein component of the TFIID factor.", "text_with_entity_marker": "We have therefore investigated whether the octamer binding proteins might physically interact with TBP, the [E1]TATA box binding protein[/E1] component of the [E2]TFIID[/E2] factor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA box binding protein", "entity_1_idx": [[108, 132]], "entity_1_idx_in_text_with_entity_marker": [112, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1158_AIMed.d137.s1158.p0", "text": "By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2.", "text_with_entity_marker": "By using several different experimental systems we show that [E1]TBP[/E1] efficiently associates with [E2]Oct1[/E2] and Oct2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1158_AIMed.d137.s1158.p1", "text": "By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2.", "text_with_entity_marker": "By using several different experimental systems we show that [E1]TBP[/E1] efficiently associates with Oct1 and [E2]Oct2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1158_AIMed.d137.s1158.p2", "text": "By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2.", "text_with_entity_marker": "By using several different experimental systems we show that TBP efficiently associates with [E1]Oct1[/E1] and [E2]Oct2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct1", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[102, 106]], "entity_2_idx_in_text_with_entity_marker": [115, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1161_AIMed.d137.s1161.p0", "text": "We show that the POU homeodomain of Oct2 and the evolutionarily conserved C-terminal core domain of TBP are both required and sufficient for the interaction.", "text_with_entity_marker": "We show that the POU homeodomain of [E1]Oct2[/E1] and the evolutionarily conserved C-terminal core domain of [E2]TBP[/E2] are both required and sufficient for the interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oct2", "entity_1_idx": [[36, 40]], "entity_1_idx_in_text_with_entity_marker": [40, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[100, 103]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1162_AIMed.d137.s1162.p0", "text": "The Oct1 POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with TBP.", "text_with_entity_marker": "The [E1]Oct1[/E1] POU domain, which is highly homologous to the [E2]Oct2[/E2] POU domain, likewise mediates interaction with TBP.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct1", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1162_AIMed.d137.s1162.p1", "text": "The Oct1 POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with TBP.", "text_with_entity_marker": "The [E1]Oct1[/E1] POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with [E2]TBP[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oct1", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[107, 110]], "entity_2_idx_in_text_with_entity_marker": [120, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1162_AIMed.d137.s1162.p2", "text": "The Oct1 POU domain, which is highly homologous to the Oct2 POU domain, likewise mediates interaction with TBP.", "text_with_entity_marker": "The Oct1 POU domain, which is highly homologous to the [E1]Oct2[/E1] POU domain, likewise mediates interaction with [E2]TBP[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct2", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[107, 110]], "entity_2_idx_in_text_with_entity_marker": [120, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1163_AIMed.d137.s1163.p0", "text": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "text_with_entity_marker": "The interaction can also be observed in vivo, as [E1]TBP[/E1] can be co-precipitated with [E2]Oct2[/E2] from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1163_AIMed.d137.s1163.p1", "text": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "text_with_entity_marker": "The interaction can also be observed in vivo, as [E1]TBP[/E1] can be co-precipitated with Oct2 from co-transfected Cos1 cells and [E2]TBP[/E2] co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1163_AIMed.d137.s1163.p2", "text": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "text_with_entity_marker": "The interaction can also be observed in vivo, as [E1]TBP[/E1] can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous [E2]Oct1[/E2] from HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct1", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1163_AIMed.d137.s1163.p3", "text": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "text_with_entity_marker": "The interaction can also be observed in vivo, as TBP can be co-precipitated with [E1]Oct2[/E1] from co-transfected Cos1 cells and [E2]TBP[/E2] co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct2", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1163_AIMed.d137.s1163.p4", "text": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "text_with_entity_marker": "The interaction can also be observed in vivo, as TBP can be co-precipitated with [E1]Oct2[/E1] from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous [E2]Oct1[/E2] from HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Oct2", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct1", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1163_AIMed.d137.s1163.p5", "text": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and TBP co-immunoprecipitates with the endogenous Oct1 from HeLa cells.", "text_with_entity_marker": "The interaction can also be observed in vivo, as TBP can be co-precipitated with Oct2 from co-transfected Cos1 cells and [E1]TBP[/E1] co-immunoprecipitates with the endogenous [E2]Oct1[/E2] from HeLa cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct1", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d137.s1164_AIMed.d137.s1164.p0", "text": "Co-transfection of human TBP and Oct2 expression vectors into B cells resulted in a synergistic activation of an octamer motif containing promoter.", "text_with_entity_marker": "Co-transfection of human [E1]TBP[/E1] and [E2]Oct2[/E2] expression vectors into B cells resulted in a synergistic activation of an octamer motif containing promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Oct2", "entity_2_idx": [[33, 37]], "entity_2_idx_in_text_with_entity_marker": [46, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s996_AIMed.d118.s996.p0", "text": "The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.", "text_with_entity_marker": "The [E1]p21[/E1] inhibitor of cyclin-dependent kinases controls DNA replication by interaction with [E2]PCNA[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s997_AIMed.d118.s997.p0", "text": "The p53 tumour-suppressor protein controls the expression of a gene encoding the p21 cyclin-dependent protein kinase (CDK) regulator.", "text_with_entity_marker": "The [E1]p53[/E1] tumour-suppressor protein controls the expression of a gene encoding the [E2]p21[/E2] cyclin-dependent protein kinase (CDK) regulator.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[81, 84]], "entity_2_idx_in_text_with_entity_marker": [94, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s998_AIMed.d118.s998.p0", "text": "Levels of p21 protein are increased in senescent cells and p21 overexpression blocks the growth of tumour cells.", "text_with_entity_marker": "Levels of [E1]p21[/E1] protein are increased in senescent cells and [E2]p21[/E2] overexpression blocks the growth of tumour cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[10, 13]], "entity_1_idx_in_text_with_entity_marker": [14, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s999_AIMed.d118.s999.p0", "text": "In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA).", "text_with_entity_marker": "In normal human cells, but not in many tumour cells, [E1]p21[/E1] exists in a quaternary complex with a cyclin, a CDK, and the [E2]proliferating-cell nuclear antigen[/E2] (PCNA).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "proliferating-cell nuclear antigen", "entity_2_idx": [[118, 152]], "entity_2_idx_in_text_with_entity_marker": [131, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s999_AIMed.d118.s999.p1", "text": "In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA).", "text_with_entity_marker": "In normal human cells, but not in many tumour cells, [E1]p21[/E1] exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen ([E2]PCNA[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s999_AIMed.d118.s999.p2", "text": "In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA).", "text_with_entity_marker": "In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the [E1]proliferating-cell nuclear antigen[/E1] ([E2]PCNA[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "proliferating-cell nuclear antigen", "entity_1_idx": [[118, 152]], "entity_1_idx_in_text_with_entity_marker": [122, 156], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1000_AIMed.d118.s1000.p0", "text": "p21 controls CDK activity, thereby affecting cell-cycle control, whereas PCNA functions in both DNA replication and repair.", "text_with_entity_marker": "[E1]p21[/E1] controls CDK activity, thereby affecting cell-cycle control, whereas [E2]PCNA[/E2] functions in both DNA replication and repair.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[73, 77]], "entity_2_idx_in_text_with_entity_marker": [86, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1001_AIMed.d118.s1001.p0", "text": "Here we use simian virus 40 DNA replication in vitro to show than p21 directly inhibits PCNA-dependent DNA replication in the absence of a cyclin/CDK.", "text_with_entity_marker": "Here we use simian virus 40 DNA replication in vitro to show than [E1]p21[/E1] directly inhibits [E2]PCNA[/E2]-dependent DNA replication in the absence of a cyclin/CDK.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[88, 92]], "entity_2_idx_in_text_with_entity_marker": [101, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1002_AIMed.d118.s1002.p0", "text": "Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase.", "text_with_entity_marker": "Furthermore, [E1]p21[/E1] blocks the ability of [E2]PCNA[/E2] to activate DNA polymerase delta, the principal replicative DNA polymerase.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[39, 43]], "entity_2_idx_in_text_with_entity_marker": [52, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1002_AIMed.d118.s1002.p1", "text": "Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase.", "text_with_entity_marker": "Furthermore, [E1]p21[/E1] blocks the ability of PCNA to activate [E2]DNA polymerase delta[/E2], the principal replicative DNA polymerase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DNA polymerase delta", "entity_2_idx": [[56, 76]], "entity_2_idx_in_text_with_entity_marker": [69, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1002_AIMed.d118.s1002.p2", "text": "Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase.", "text_with_entity_marker": "Furthermore, p21 blocks the ability of [E1]PCNA[/E1] to activate [E2]DNA polymerase delta[/E2], the principal replicative DNA polymerase.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PCNA", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DNA polymerase delta", "entity_2_idx": [[56, 76]], "entity_2_idx_in_text_with_entity_marker": [69, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1003_AIMed.d118.s1003.p0", "text": "This regulation results from a direct interaction between p21 and PCNA.", "text_with_entity_marker": "This regulation results from a direct interaction between [E1]p21[/E1] and [E2]PCNA[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1004_AIMed.d118.s1004.p0", "text": "Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.", "text_with_entity_marker": "Thus, during [E1]p53[/E1]-mediated suppression of cell proliferation, [E2]p21[/E2] and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1004_AIMed.d118.s1004.p1", "text": "Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.", "text_with_entity_marker": "Thus, during [E1]p53[/E1]-mediated suppression of cell proliferation, p21 and [E2]PCNA[/E2] may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d118.s1004_AIMed.d118.s1004.p2", "text": "Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.", "text_with_entity_marker": "Thus, during p53-mediated suppression of cell proliferation, [E1]p21[/E1] and [E2]PCNA[/E2] may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1402_AIMed.d167.s1402.p0", "text": "The glut 1 glucose transporter interacts with calnexin and calreticulin.", "text_with_entity_marker": "The [E1]glut 1[/E1] glucose transporter interacts with [E2]calnexin[/E2] and calreticulin.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "glut 1", "entity_1_idx": [[4, 10]], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[46, 54]], "entity_2_idx_in_text_with_entity_marker": [59, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1402_AIMed.d167.s1402.p1", "text": "The glut 1 glucose transporter interacts with calnexin and calreticulin.", "text_with_entity_marker": "The [E1]glut 1[/E1] glucose transporter interacts with calnexin and [E2]calreticulin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "glut 1", "entity_1_idx": [[4, 10]], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[59, 71]], "entity_2_idx_in_text_with_entity_marker": [72, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1402_AIMed.d167.s1402.p2", "text": "The glut 1 glucose transporter interacts with calnexin and calreticulin.", "text_with_entity_marker": "The glut 1 glucose transporter interacts with [E1]calnexin[/E1] and [E2]calreticulin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[46, 54]], "entity_1_idx_in_text_with_entity_marker": [50, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[59, 71]], "entity_2_idx_in_text_with_entity_marker": [72, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1405_AIMed.d167.s1405.p0", "text": "A truncated version of the integral membrane glycoprotein Glut 1 (GT155) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes.", "text_with_entity_marker": "A truncated version of the integral membrane glycoprotein [E1]Glut 1[/E1] ([E2]GT155[/E2]) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Glut 1", "entity_1_idx": [[58, 64]], "entity_1_idx_in_text_with_entity_marker": [62, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1406_AIMed.d167.s1406.p0", "text": "Following immunoprecipitation with an anticalnexin antiserum, a cross-linker-independent association was observed between GT155 and calnexin.", "text_with_entity_marker": "Following immunoprecipitation with an anticalnexin antiserum, a cross-linker-independent association was observed between [E1]GT155[/E1] and [E2]calnexin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GT155", "entity_1_idx": [[122, 127]], "entity_1_idx_in_text_with_entity_marker": [126, 131], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[132, 140]], "entity_2_idx_in_text_with_entity_marker": [145, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1407_AIMed.d167.s1407.p0", "text": "In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa).", "text_with_entity_marker": "In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of [E1]GT155[/E1] and a protein of approximately 60 kDa designated [E2]CAP-60[/E2] (calnexin-associated protein of 60 kDa).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GT155", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CAP-60", "entity_2_idx": [[166, 172]], "entity_2_idx_in_text_with_entity_marker": [179, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1407_AIMed.d167.s1407.p1", "text": "In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa).", "text_with_entity_marker": "In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of [E1]GT155[/E1] and a protein of approximately 60 kDa designated CAP-60 ([E2]calnexin-associated protein[/E2] of 60 kDa).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GT155", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin-associated protein", "entity_2_idx": [[174, 201]], "entity_2_idx_in_text_with_entity_marker": [187, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1407_AIMed.d167.s1407.p2", "text": "In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP-60 (calnexin-associated protein of 60 kDa).", "text_with_entity_marker": "In addition, the anti-calnexin antiserum immunoprecipitated a UV-dependent cross-linking product consisting of GT155 and a protein of approximately 60 kDa designated [E1]CAP-60[/E1] ([E2]calnexin-associated protein[/E2] of 60 kDa).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CAP-60", "entity_1_idx": [[166, 172]], "entity_1_idx_in_text_with_entity_marker": [170, 176], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin-associated protein", "entity_2_idx": [[174, 201]], "entity_2_idx_in_text_with_entity_marker": [187, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p0", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the [E1]GT155[/E1]-[E2]calnexin[/E2] and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GT155", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[15, 23]], "entity_2_idx_in_text_with_entity_marker": [28, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p1", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the [E1]GT155[/E1]-calnexin and the [E2]GT155[/E2]-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p2", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the [E1]GT155[/E1]-calnexin and the GT155-[E2]CAP-60[/E2] interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CAP-60", "entity_2_idx": [[38, 44]], "entity_2_idx_in_text_with_entity_marker": [51, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p3", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the [E1]GT155[/E1]-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on [E2]GT155[/E2], a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p4", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the [E1]GT155[/E1]-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many [E2]calnexin[/E2] interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[170, 178]], "entity_2_idx_in_text_with_entity_marker": [183, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p5", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-[E1]calnexin[/E1] and the [E2]GT155[/E2]-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p6", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-[E1]calnexin[/E1] and the GT155-[E2]CAP-60[/E2] interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CAP-60", "entity_2_idx": [[38, 44]], "entity_2_idx_in_text_with_entity_marker": [51, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p7", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-[E1]calnexin[/E1] and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on [E2]GT155[/E2], a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p8", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-[E1]calnexin[/E1] and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many [E2]calnexin[/E2] interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[170, 178]], "entity_2_idx_in_text_with_entity_marker": [183, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p9", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-calnexin and the [E1]GT155[/E1]-[E2]CAP-60[/E2] interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GT155", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CAP-60", "entity_2_idx": [[38, 44]], "entity_2_idx_in_text_with_entity_marker": [51, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p10", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-calnexin and the [E1]GT155[/E1]-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on [E2]GT155[/E2], a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p11", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-calnexin and the [E1]GT155[/E1]-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many [E2]calnexin[/E2] interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[170, 178]], "entity_2_idx_in_text_with_entity_marker": [183, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p12", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-calnexin and the GT155-[E1]CAP-60[/E1] interactions were dependent on the presence of a correctly modified oligosaccharide group on [E2]GT155[/E2], a characteristic of many calnexin interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CAP-60", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p13", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-calnexin and the GT155-[E1]CAP-60[/E1] interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many [E2]calnexin[/E2] interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CAP-60", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[170, 178]], "entity_2_idx_in_text_with_entity_marker": [183, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1408_AIMed.d167.s1408.p14", "text": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155, a characteristic of many calnexin interactions.", "text_with_entity_marker": "Both the GT155-calnexin and the GT155-CAP-60 interactions were dependent on the presence of a correctly modified oligosaccharide group on [E1]GT155[/E1], a characteristic of many [E2]calnexin[/E2] interactions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[138, 143]], "entity_1_idx_in_text_with_entity_marker": [142, 147], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[170, 178]], "entity_2_idx_in_text_with_entity_marker": [183, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1409_AIMed.d167.s1409.p0", "text": "A GT155 mutant that was not glycosylated (AGGT155) did not associate with calnexin or CAP-60.", "text_with_entity_marker": "A [E1]GT155[/E1] mutant that was not glycosylated (AGGT155) did not associate with [E2]calnexin[/E2] or CAP-60.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[74, 82]], "entity_2_idx_in_text_with_entity_marker": [87, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1409_AIMed.d167.s1409.p1", "text": "A GT155 mutant that was not glycosylated (AGGT155) did not associate with calnexin or CAP-60.", "text_with_entity_marker": "A [E1]GT155[/E1] mutant that was not glycosylated (AGGT155) did not associate with calnexin or [E2]CAP-60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GT155", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CAP-60", "entity_2_idx": [[86, 92]], "entity_2_idx_in_text_with_entity_marker": [99, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1409_AIMed.d167.s1409.p2", "text": "A GT155 mutant that was not glycosylated (AGGT155) did not associate with calnexin or CAP-60.", "text_with_entity_marker": "A GT155 mutant that was not glycosylated (AGGT155) did not associate with [E1]calnexin[/E1] or [E2]CAP-60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[74, 82]], "entity_1_idx_in_text_with_entity_marker": [78, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CAP-60", "entity_2_idx": [[86, 92]], "entity_2_idx_in_text_with_entity_marker": [99, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1410_AIMed.d167.s1410.p0", "text": "Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.", "text_with_entity_marker": "[E1]Calreticulin[/E1], the soluble homologue of [E2]calnexin[/E2], was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Calreticulin", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calnexin", "entity_2_idx": [[39, 47]], "entity_2_idx_in_text_with_entity_marker": [52, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1410_AIMed.d167.s1410.p1", "text": "Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.", "text_with_entity_marker": "[E1]Calreticulin[/E1], the soluble homologue of calnexin, was also shown to interact with [E2]GT155[/E2] only when the protein bore a correctly modified oligosaccharide group.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Calreticulin", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1410_AIMed.d167.s1410.p2", "text": "Calreticulin, the soluble homologue of calnexin, was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group.", "text_with_entity_marker": "Calreticulin, the soluble homologue of [E1]calnexin[/E1], was also shown to interact with [E2]GT155[/E2] only when the protein bore a correctly modified oligosaccharide group.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GT155", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1411_AIMed.d167.s1411.p0", "text": "Thus, our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation-dependent manner.", "text_with_entity_marker": "Thus, our data show that both [E1]calnexin[/E1] and [E2]calreticulin[/E2] interact with Glut 1 in a glycosylation-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calnexin", "entity_1_idx": [[30, 38]], "entity_1_idx_in_text_with_entity_marker": [34, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calreticulin", "entity_2_idx": [[43, 55]], "entity_2_idx_in_text_with_entity_marker": [56, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1411_AIMed.d167.s1411.p1", "text": "Thus, our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation-dependent manner.", "text_with_entity_marker": "Thus, our data show that both [E1]calnexin[/E1] and calreticulin interact with [E2]Glut 1[/E2] in a glycosylation-dependent manner.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "calnexin", "entity_1_idx": [[30, 38]], "entity_1_idx_in_text_with_entity_marker": [34, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Glut 1", "entity_2_idx": [[70, 76]], "entity_2_idx_in_text_with_entity_marker": [83, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d167.s1411_AIMed.d167.s1411.p2", "text": "Thus, our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation-dependent manner.", "text_with_entity_marker": "Thus, our data show that both calnexin and [E1]calreticulin[/E1] interact with [E2]Glut 1[/E2] in a glycosylation-dependent manner.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "calreticulin", "entity_1_idx": [[43, 55]], "entity_1_idx_in_text_with_entity_marker": [47, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Glut 1", "entity_2_idx": [[70, 76]], "entity_2_idx_in_text_with_entity_marker": [83, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1091_AIMed.d128.s1091.p0", "text": "The X-ray structure of a growth hormone-prolactin receptor complex.", "text_with_entity_marker": "The X-ray structure of a [E1]growth hormone[/E1]-[E2]prolactin[/E2] receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "growth hormone", "entity_1_idx": [[25, 39]], "entity_1_idx_in_text_with_entity_marker": [29, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "prolactin", "entity_2_idx": [[40, 49]], "entity_2_idx_in_text_with_entity_marker": [53, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1092_AIMed.d128.s1092.p0", "text": "The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "text_with_entity_marker": "The human pituitary hormones, [E1]growth hormone[/E1] ([E2]hGH[/E2]) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "growth hormone", "entity_1_idx": [[30, 44]], "entity_1_idx_in_text_with_entity_marker": [34, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[46, 49]], "entity_2_idx_in_text_with_entity_marker": [59, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1092_AIMed.d128.s1092.p1", "text": "The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "text_with_entity_marker": "The human pituitary hormones, [E1]growth hormone[/E1] (hGH) and [E2]prolactin[/E2] (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "growth hormone", "entity_1_idx": [[30, 44]], "entity_1_idx_in_text_with_entity_marker": [34, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "prolactin", "entity_2_idx": [[55, 64]], "entity_2_idx_in_text_with_entity_marker": [68, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1092_AIMed.d128.s1092.p2", "text": "The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "text_with_entity_marker": "The human pituitary hormones, [E1]growth hormone[/E1] (hGH) and prolactin ([E2]hPRL[/E2]), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "growth hormone", "entity_1_idx": [[30, 44]], "entity_1_idx_in_text_with_entity_marker": [34, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRL", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1092_AIMed.d128.s1092.p3", "text": "The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "text_with_entity_marker": "The human pituitary hormones, growth hormone ([E1]hGH[/E1]) and [E2]prolactin[/E2] (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "prolactin", "entity_2_idx": [[55, 64]], "entity_2_idx_in_text_with_entity_marker": [68, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1092_AIMed.d128.s1092.p4", "text": "The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "text_with_entity_marker": "The human pituitary hormones, growth hormone ([E1]hGH[/E1]) and prolactin ([E2]hPRL[/E2]), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRL", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1092_AIMed.d128.s1092.p5", "text": "The human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "text_with_entity_marker": "The human pituitary hormones, growth hormone (hGH) and [E1]prolactin[/E1] ([E2]hPRL[/E2]), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "prolactin", "entity_1_idx": [[55, 64]], "entity_1_idx_in_text_with_entity_marker": [59, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRL", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1094_AIMed.d128.s1094.p0", "text": "The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "text_with_entity_marker": "The [E1]hGH[/E1] and [E2]hPRL[/E2] receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRL", "entity_2_idx": [[12, 16]], "entity_2_idx_in_text_with_entity_marker": [25, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1094_AIMed.d128.s1094.p1", "text": "The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "text_with_entity_marker": "The [E1]hGH[/E1] and hPRL receptors ([E2]hGHR[/E2] and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hGH", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[28, 32]], "entity_2_idx_in_text_with_entity_marker": [41, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1094_AIMed.d128.s1094.p2", "text": "The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "text_with_entity_marker": "The [E1]hGH[/E1] and hPRL receptors (hGHR and [E2]hPRLR[/E2], respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1094_AIMed.d128.s1094.p3", "text": "The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "text_with_entity_marker": "The hGH and [E1]hPRL[/E1] receptors ([E2]hGHR[/E2] and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRL", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[28, 32]], "entity_2_idx_in_text_with_entity_marker": [41, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1094_AIMed.d128.s1094.p4", "text": "The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "text_with_entity_marker": "The hGH and [E1]hPRL[/E1] receptors (hGHR and [E2]hPRLR[/E2], respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hPRL", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1094_AIMed.d128.s1094.p5", "text": "The hGH and hPRL receptors (hGHR and hPRLR, respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "text_with_entity_marker": "The hGH and hPRL receptors ([E1]hGHR[/E1] and [E2]hPRLR[/E2], respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGHR", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p0", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of [E1]hGH[/E1], activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. [E2]hPRL[/E2] does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRL", "entity_2_idx": [[247, 251]], "entity_2_idx_in_text_with_entity_marker": [260, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p1", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of [E1]hGH[/E1], activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the [E2]hGH[/E2] receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[273, 276]], "entity_2_idx_in_text_with_entity_marker": [286, 289], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p2", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of [E1]hGH[/E1], activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but [E2]hGH[/E2] binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[291, 294]], "entity_2_idx_in_text_with_entity_marker": [304, 307], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p3", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of [E1]hGH[/E1], activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the [E2]hGHR[/E2] and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[313, 317]], "entity_2_idx_in_text_with_entity_marker": [326, 330], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p4", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of [E1]hGH[/E1], activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and [E2]hPRLR[/E2], and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[322, 327]], "entity_2_idx_in_text_with_entity_marker": [335, 340], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p5", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of [E1]hGH[/E1], activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on [E2]hGH[/E2] overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[399, 402]], "entity_2_idx_in_text_with_entity_marker": [412, 415], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p6", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. [E1]hPRL[/E1] does not bind to the [E2]hGH[/E2] receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRL", "entity_1_idx": [[247, 251]], "entity_1_idx_in_text_with_entity_marker": [251, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[273, 276]], "entity_2_idx_in_text_with_entity_marker": [286, 289], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p7", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. [E1]hPRL[/E1] does not bind to the hGH receptor, but [E2]hGH[/E2] binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRL", "entity_1_idx": [[247, 251]], "entity_1_idx_in_text_with_entity_marker": [251, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[291, 294]], "entity_2_idx_in_text_with_entity_marker": [304, 307], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p8", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. [E1]hPRL[/E1] does not bind to the hGH receptor, but hGH binds to both the [E2]hGHR[/E2] and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRL", "entity_1_idx": [[247, 251]], "entity_1_idx_in_text_with_entity_marker": [251, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[313, 317]], "entity_2_idx_in_text_with_entity_marker": [326, 330], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p9", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. [E1]hPRL[/E1] does not bind to the hGH receptor, but hGH binds to both the hGHR and [E2]hPRLR[/E2], and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRL", "entity_1_idx": [[247, 251]], "entity_1_idx_in_text_with_entity_marker": [251, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[322, 327]], "entity_2_idx_in_text_with_entity_marker": [335, 340], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p10", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. [E1]hPRL[/E1] does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on [E2]hGH[/E2] overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRL", "entity_1_idx": [[247, 251]], "entity_1_idx_in_text_with_entity_marker": [251, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[399, 402]], "entity_2_idx_in_text_with_entity_marker": [412, 415], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p11", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the [E1]hGH[/E1] receptor, but [E2]hGH[/E2] binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[273, 276]], "entity_1_idx_in_text_with_entity_marker": [277, 280], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[291, 294]], "entity_2_idx_in_text_with_entity_marker": [304, 307], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p12", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the [E1]hGH[/E1] receptor, but hGH binds to both the [E2]hGHR[/E2] and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[273, 276]], "entity_1_idx_in_text_with_entity_marker": [277, 280], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[313, 317]], "entity_2_idx_in_text_with_entity_marker": [326, 330], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p13", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the [E1]hGH[/E1] receptor, but hGH binds to both the hGHR and [E2]hPRLR[/E2], and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[273, 276]], "entity_1_idx_in_text_with_entity_marker": [277, 280], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[322, 327]], "entity_2_idx_in_text_with_entity_marker": [335, 340], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p14", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the [E1]hGH[/E1] receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on [E2]hGH[/E2] overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[273, 276]], "entity_1_idx_in_text_with_entity_marker": [277, 280], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[399, 402]], "entity_2_idx_in_text_with_entity_marker": [412, 415], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p15", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but [E1]hGH[/E1] binds to both the [E2]hGHR[/E2] and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hGH", "entity_1_idx": [[291, 294]], "entity_1_idx_in_text_with_entity_marker": [295, 298], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[313, 317]], "entity_2_idx_in_text_with_entity_marker": [326, 330], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p16", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but [E1]hGH[/E1] binds to both the hGHR and [E2]hPRLR[/E2], and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hGH", "entity_1_idx": [[291, 294]], "entity_1_idx_in_text_with_entity_marker": [295, 298], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[322, 327]], "entity_2_idx_in_text_with_entity_marker": [335, 340], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p17", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but [E1]hGH[/E1] binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on [E2]hGH[/E2] overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[291, 294]], "entity_1_idx_in_text_with_entity_marker": [295, 298], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[399, 402]], "entity_2_idx_in_text_with_entity_marker": [412, 415], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p18", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the [E1]hGHR[/E1] and [E2]hPRLR[/E2], and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGHR", "entity_1_idx": [[313, 317]], "entity_1_idx_in_text_with_entity_marker": [317, 321], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[322, 327]], "entity_2_idx_in_text_with_entity_marker": [335, 340], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p19", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the [E1]hGHR[/E1] and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on [E2]hGH[/E2] overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGHR", "entity_1_idx": [[313, 317]], "entity_1_idx_in_text_with_entity_marker": [317, 321], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[399, 402]], "entity_2_idx_in_text_with_entity_marker": [412, 415], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1097_AIMed.d128.s1097.p20", "text": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and hPRLR, and mutagenesis studies have shown that the receptor-binding sites on hGH overlap.", "text_with_entity_marker": "In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex. hPRL does not bind to the hGH receptor, but hGH binds to both the hGHR and [E1]hPRLR[/E1], and mutagenesis studies have shown that the receptor-binding sites on [E2]hGH[/E2] overlap.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hPRLR", "entity_1_idx": [[322, 327]], "entity_1_idx_in_text_with_entity_marker": [326, 331], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[399, 402]], "entity_2_idx_in_text_with_entity_marker": [412, 415], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1098_AIMed.d128.s1098.p0", "text": "We present here the crystal structure of the 1:1 complex of hGH bound to the extracellular domain of the hPRLR.", "text_with_entity_marker": "We present here the crystal structure of the 1:1 complex of [E1]hGH[/E1] bound to the extracellular domain of the [E2]hPRLR[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hGH", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hPRLR", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1099_AIMed.d128.s1099.p0", "text": "Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.", "text_with_entity_marker": "Comparisons with the [E1]hGH[/E1]-[E2]hGHR[/E2] complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hGH", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGHR", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1099_AIMed.d128.s1099.p1", "text": "Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.", "text_with_entity_marker": "Comparisons with the [E1]hGH[/E1]-hGHR complex reveal how [E2]hGH[/E2] can bind to the two distinctly different receptor binding surfaces.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGH", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d128.s1099_AIMed.d128.s1099.p2", "text": "Comparisons with the hGH-hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces.", "text_with_entity_marker": "Comparisons with the hGH-[E1]hGHR[/E1] complex reveal how [E2]hGH[/E2] can bind to the two distinctly different receptor binding surfaces.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hGHR", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGH", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1140_AIMed.d134.s1140.p0", "text": "B61 is a ligand for the ECK receptor protein-tyrosine kinase.", "text_with_entity_marker": "[E1]B61[/E1] is a ligand for the [E2]ECK[/E2] receptor protein-tyrosine kinase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B61", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[24, 27]], "entity_2_idx_in_text_with_entity_marker": [37, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1140_AIMed.d134.s1140.p1", "text": "B61 is a ligand for the ECK receptor protein-tyrosine kinase.", "text_with_entity_marker": "[E1]B61[/E1] is a ligand for the [E2]ECK receptor protein-tyrosine kinase[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "B61", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK receptor protein-tyrosine kinase", "entity_2_idx": [[24, 60]], "entity_2_idx_in_text_with_entity_marker": [37, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1140_AIMed.d134.s1140.p2", "text": "B61 is a ligand for the ECK receptor protein-tyrosine kinase.", "text_with_entity_marker": "B61 is a ligand for the [E1-E2]ECK[/E1] receptor protein-tyrosine kinase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK[/E1] receptor protein-tyrosine kinase", "entity_2_idx": [[24, 60]], "entity_2_idx_in_text_with_entity_marker": [31, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1141_AIMed.d134.s1141.p0", "text": "A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.", "text_with_entity_marker": "A protein ligand for the [E1-E2]ECK[/E1] receptor protein-tyrosine kinase[/E2] has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK[/E1] receptor protein-tyrosine kinase", "entity_2_idx": [[25, 61]], "entity_2_idx_in_text_with_entity_marker": [32, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1141_AIMed.d134.s1141.p1", "text": "A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.", "text_with_entity_marker": "A protein ligand for the [E1]ECK[/E1] receptor protein-tyrosine kinase has been isolated by using the extracellular domain ([E2]ECK[/E2]-X) of the receptor as an affinity reagent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[115, 118]], "entity_2_idx_in_text_with_entity_marker": [128, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1141_AIMed.d134.s1141.p2", "text": "A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.", "text_with_entity_marker": "A protein ligand for the [E1]ECK receptor protein-tyrosine kinase[/E1] has been isolated by using the extracellular domain ([E2]ECK[/E2]-X) of the receptor as an affinity reagent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK receptor protein-tyrosine kinase", "entity_1_idx": [[25, 61]], "entity_1_idx_in_text_with_entity_marker": [29, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[115, 118]], "entity_2_idx_in_text_with_entity_marker": [128, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1143_AIMed.d134.s1143.p0", "text": "Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of B61, a protein previously identified as the product of an early response gene induced by tumour necrosis factor-alpha.", "text_with_entity_marker": "Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of [E1]B61[/E1], a protein previously identified as the product of an early response gene induced by [E2]tumour necrosis factor-alpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B61", "entity_1_idx": [[161, 164]], "entity_1_idx_in_text_with_entity_marker": [165, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tumour necrosis factor-alpha", "entity_2_idx": [[250, 278]], "entity_2_idx_in_text_with_entity_marker": [263, 291], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1144_AIMed.d134.s1144.p0", "text": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.", "text_with_entity_marker": "We report here that recombinant [E1]B61[/E1] induces autophosphorylation of [E2]ECK[/E2] in intact cells, consistent with B61 being an authentic ligand for ECK.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "B61", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[67, 70]], "entity_2_idx_in_text_with_entity_marker": [80, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1144_AIMed.d134.s1144.p1", "text": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.", "text_with_entity_marker": "We report here that recombinant [E1]B61[/E1] induces autophosphorylation of ECK in intact cells, consistent with [E2]B61[/E2] being an authentic ligand for ECK.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B61", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B61", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1144_AIMed.d134.s1144.p2", "text": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.", "text_with_entity_marker": "We report here that recombinant [E1]B61[/E1] induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for [E2]ECK[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B61", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1144_AIMed.d134.s1144.p3", "text": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.", "text_with_entity_marker": "We report here that recombinant B61 induces autophosphorylation of [E1]ECK[/E1] in intact cells, consistent with [E2]B61[/E2] being an authentic ligand for ECK.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK", "entity_1_idx": [[67, 70]], "entity_1_idx_in_text_with_entity_marker": [71, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B61", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1144_AIMed.d134.s1144.p4", "text": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.", "text_with_entity_marker": "We report here that recombinant B61 induces autophosphorylation of [E1]ECK[/E1] in intact cells, consistent with B61 being an authentic ligand for [E2]ECK[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK", "entity_1_idx": [[67, 70]], "entity_1_idx_in_text_with_entity_marker": [71, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1144_AIMed.d134.s1144.p5", "text": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.", "text_with_entity_marker": "We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with [E1]B61[/E1] being an authentic ligand for [E2]ECK[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "B61", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ECK", "entity_2_idx": [[138, 141]], "entity_2_idx_in_text_with_entity_marker": [151, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d134.s1145_AIMed.d134.s1145.p0", "text": "ECK is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH, and we suggest that ligands for other members of this family will be related to B61, and can be isolated in the same way.", "text_with_entity_marker": "[E1]ECK[/E1] is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH, and we suggest that ligands for other members of this family will be related to [E2]B61[/E2], and can be isolated in the same way.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ECK", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B61", "entity_2_idx": [[169, 172]], "entity_2_idx_in_text_with_entity_marker": [182, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
